Chimeric Antigen Receptor T-Cell Therapy Targeting CD19 (CART-19): A Comprehensive Report

1. Introduction to CART-19 Therapy

Defining CART-19: A Revolutionary Cellular Immunotherapy

Chimeric Antigen Receptor T-cell (CART) therapy targeting the CD19 protein (CART-19) represents a transformative class of adoptive cell transfer immunotherapy. This innovative approach involves the genetic modification of a patient's own T-lymphocytes (autologous T-cells) to recognize and eliminate cancer cells that express the CD19 antigen on their surface.[1] This therapy has emerged as a powerful and potentially curative option, particularly for patients with various B-cell hematological malignancies that are relapsed or refractory (r/r) to conventional treatments.[1] The personalized nature of CART-19 therapy, where T-cells are harvested from the patient, engineered ex vivo, expanded to therapeutic doses, and then re-infused, distinguishes it fundamentally from traditional pharmaceutical agents like small molecules or monoclonal antibodies.[1] The unprecedented efficacy observed in clinical trials has led to the approval of several CART-19 products by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).[3]

The development and application of CART-19 therapy signify a substantial paradigm shift in oncology, moving from "drug-centric" treatments to "living drug" therapies.[1] These genetically engineered cells are not static; they can proliferate, persist, and exert their effector functions over extended periods within the patient, leading to dynamic pharmacokinetic and pharmacodynamic profiles unlike conventional drugs.[3] This "living" nature also contributes to unique toxicity profiles, such as Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which are driven by the potent activation of the engineered T-cells and subsequent cytokine release.[14] The potential for long-term immunological memory and surveillance further underscores the distinctiveness of this therapeutic modality.[13] Consequently, the entire lifecycle of CART-19 therapy, encompassing development, manufacturing, administration, and patient monitoring, demands specialized approaches and infrastructure.

The Significance of the CD19 Target in B-Cell Malignancies

The CD19 protein is a transmembrane glycoprotein that is an ideal target for B-cell directed immunotherapies. It is consistently expressed on the surface of normal B-lymphocytes throughout most stages of their development, from early B-cell precursors to mature B-cells, but is notably absent on hematopoietic stem cells and most other non-hematopoietic tissues.[1] Crucially, CD19 is also expressed on the vast majority of malignant B-cells, including those found in various forms of leukemia and lymphoma.[1]

This expression pattern—broadly present on malignant B-cells and normal B-cells but restricted outside the B-cell lineage—makes CD19 an attractive target. The targeting of CD19 by CAR T-cells allows for potent anti-tumor activity against B-cell cancers while generally sparing other essential cell types, although it does lead to the depletion of the normal B-cell population.[1] The clinical success of numerous CART-19 products has firmly validated CD19 as a critical therapeutic target in the management of B-cell malignancies.[1] However, this specificity also inherently leads to on-target, off-tumor effects, primarily B-cell aplasia. This depletion of normal B-cells results in hypogammaglobulinemia and an increased susceptibility to infections, necessitating long-term monitoring and often prophylactic interventions such as intravenous immunoglobulin (IVIG) replacement.[16] This illustrates a core principle in CAR T-cell therapy: the target antigen's expression profile dictates not only the therapy's efficacy but also a predictable set of adverse events that require proactive and specialized management strategies.

2. Mechanism of Action of CART-19 Cells

Engineering T-Cells: Structure of Chimeric Antigen Receptors (CARs)

Chimeric Antigen Receptors (CARs) are synthetic, engineered receptors that are genetically introduced into T-cells, most commonly the patient's own T-cells in an autologous setting.[1] The fundamental purpose of a CAR is to redirect T-cell specificity and effector functions towards cancer cells by combining the antigen-binding capabilities of an antibody with the T-cell's intrinsic activation and signaling machinery.[1] This allows CAR T-cells to recognize and kill cancer cells in a manner independent of the Major Histocompatibility Complex (MHC), which is often downregulated by tumors to evade immune surveillance.[22]

The modular design of a CAR typically comprises several key components:

• Extracellular Antigen-Binding Domain: This domain is responsible for recognizing the target antigen on the cancer cell surface. For CART-19 therapies, this is almost universally a single-chain variable fragment (scFv) derived from a monoclonal antibody specific for the CD19 protein.[1] The choice and design of the scFv are critical for the CAR's binding affinity and specificity.
• Hinge or Spacer Region: This flexible region connects the extracellular antigen-binding domain to the transmembrane domain. Its length and composition can influence CAR expression on the T-cell surface, flexibility for antigen binding, and the distance of the CAR T-cell from the target cell, thereby impacting synaptic stability and signaling efficacy.[22]
• Transmembrane Domain: This hydrophobic segment spans the T-cell membrane, anchoring the CAR structure and transmitting signals from the extracellular antigen-binding event to the intracellular signaling domains.[22] Portions of CD8α or CD28 are commonly used.
• Intracellular Signaling Domains: These domains are critical for T-cell activation, proliferation, survival, and effector functions upon antigen engagement.
• CD3-zeta (CD3ζ) Chain: This is the primary activation domain, derived from the T-cell receptor (TCR)/CD3 complex. It contains immunoreceptor tyrosine-based activation motifs (ITAMs) that initiate T-cell signaling upon CAR ligation.[1] First-generation CARs, which contained only the CD3ζ domain, demonstrated limited clinical efficacy due to poor T-cell expansion and persistence in vivo.[11]
• Costimulatory Domain(s): To overcome the limitations of first-generation CARs, second-generation CARs were developed, incorporating one intracellular costimulatory signaling domain in tandem with CD3ζ. The most commonly used costimulatory domains in clinically approved CART-19 products are CD28 or 4-1BB (also known as CD137).[1] These domains provide crucial secondary signals that enhance T-cell proliferation, cytokine production (e.g., IL-2), survival, and persistence, leading to more robust and durable anti-tumor responses.[22] The choice of costimulatory domain significantly influences the CAR T-cell phenotype and function. CD28 costimulation is often associated with rapid T-cell expansion, potent effector functions, and a T-effector memory phenotype, but potentially shorter persistence.[17] In contrast, 4-1BB costimulation tends to promote the development of T-central memory cells, leading to more sustained T-cell persistence and potentially more durable responses, albeit sometimes with slower initial expansion kinetics.[17] This distinction in costimulatory domains can affect both the efficacy profile and the timing and nature of associated toxicities.
• Further generations of CARs have been developed. Third-generation CARs incorporate two or more costimulatory domains (e.g., CD28 and 4-1BB). Fourth-generation CARs, often termed "T-cells redirected for universal cytokine-mediated killing" (TRUCKs) or "armored CARs," are engineered to produce and secrete additional therapeutic molecules, such as pro-inflammatory cytokines (e.g., IL-12, IL-18), upon antigen engagement. These secreted factors can help to modulate the tumor microenvironment, recruit other immune cells, and further enhance the anti-tumor response.[22] Fifth-generation CARs are incorporating elements like IL-2 receptor beta-chain domains to promote cytokine-independent signaling.[23]

Target Recognition and Cancer Cell Eradication by CART-19 Cells

The fundamental mechanism by which CART-19 cells eliminate malignant B-cells begins with the specific recognition of the CD19 antigen. The scFv domain on the CAR T-cell surface directly binds to CD19 expressed on B-cells, including leukemia and lymphoma cells.[1] A critical advantage of CAR-mediated recognition is its independence from MHC presentation of antigens.[22] This allows CART-19 cells to target cancer cells even if they have downregulated MHC molecules, a common immune evasion tactic. This MHC-independent targeting contributes significantly to the broad applicability and high efficacy rates of CART-19 therapies across diverse patient populations and B-cell malignancy subtypes.

Upon successful binding of the CAR to CD19, the intracellular signaling domains (CD3ζ and the costimulatory domain, e.g., CD28 or 4-1BB) become activated.[3] This triggers a cascade of downstream signaling events within the T-cell, leading to its full activation. Activated CART-19 cells then undergo robust proliferation, significantly increasing the number of tumor-targeting effector cells in vivo. They also differentiate into cytotoxic T-lymphocytes (CTLs) and secrete a variety of cytokines and chemokines, such as interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukins (e.g., IL-2, IL-6).[3] These secreted factors can further amplify the immune response, recruit other immune cells to the tumor site, and directly contribute to tumor cell killing.

The primary mechanism of cancer cell eradication by activated CART-19 cells is direct cytotoxicity. This is mediated through the release of cytotoxic granules containing perforin and granzymes from the CAR T-cell into the immunological synapse formed with the target B-cell.[3] Perforin creates pores in the target cell membrane, allowing granzymes to enter and induce apoptosis (programmed cell death) of the CD19-positive cancer cell. The sustained activity and potential for long-term persistence of CART-19 cells aim to achieve deep and durable remissions by thoroughly eliminating CD19-expressing malignant cells from the body.[11]

3. The CART-19 Therapeutic Process: From Vein to Vein

The administration of CART-19 therapy is a complex, multi-step process that begins with the collection of a patient's T-cells and culminates in the infusion of the engineered cells back into the patient. This "vein-to-vein" timeline involves several critical stages, each with its own logistical and clinical considerations.

Patient T-Cell Collection (Leukapheresis)

The therapeutic journey for autologous CART-19 therapy commences with leukapheresis, a procedure where blood is drawn from the patient and passed through a machine that separates out the white blood cells, including T-lymphocytes.[2] The remaining blood components are returned to the patient. This collection process typically lasts between 3 to 6 hours and is performed in a specialized apheresis unit.[14] The quality and quantity of the collected T-cells are crucial for successful CAR T-cell manufacturing. Factors such as the patient's underlying disease, prior treatment history (particularly extensive chemotherapy), and overall health can impact the T-cell yield and fitness.[6] Consequently, some treatment protocols advocate for earlier collection of T-cells in the disease course, potentially before further lines of therapy might compromise T-cell health.[6]

Manufacturing: Genetic Modification, Expansion, and Quality Control

Following collection, the patient's T-cells are transported, often cryopreserved, to a centralized, Good Manufacturing Practices (GMP)-compliant facility for the intricate engineering process.[1]

• Genetic Modification: The core of the manufacturing process involves genetically modifying the isolated T-cells to express the CD19-specific CAR. This is most commonly achieved using viral vectors, predominantly lentiviral or gammaretroviral vectors, which integrate the CAR-encoding gene into the T-cell's genome.[3] Emerging technologies like CRISPR/Cas9 gene editing are also being explored as alternatives for more precise gene insertion.[3]
• Expansion: Once successfully transduced with the CAR gene, the T-cells are cultured ex vivo under conditions that promote their proliferation and expansion.[2] This phase, which can take several weeks, often involves stimulation with cytokines such as IL-2 and antibodies targeting CD3 and CD28 to drive T-cell activation and growth to achieve the necessary therapeutic dose.[3]
• Quality Control: Throughout and upon completion of the manufacturing process, the CAR T-cell product undergoes rigorous quality control testing. These tests assess the identity (presence of CAR expression), purity (percentage of CAR T-cells), potency (ability to kill target cells and produce cytokines), and safety (sterility, absence of mycoplasma, and replication-competent viral vectors) of the final product.[7]
• Cryopreservation and Logistics: The final, quality-assured CAR T-cell product is typically cryopreserved to maintain viability and then shipped back to the patient's treatment center.[6] The entire manufacturing timeline, from receipt of the patient's cells to shipment of the final product, generally spans 3 to 4 weeks, although this can vary depending on the specific product and manufacturing capacity.[27] Efforts are underway to shorten this "vein-to-vein" time, as delays can be critical for patients with aggressive, rapidly progressing malignancies.[25]

The autologous nature of current mainstream CART-19 therapies, while offering personalized treatment, introduces significant logistical complexities and potential for manufacturing variability or failure. The "vein-to-vein" time, encompassing cell collection, shipping, centralized manufacturing, quality control, and return shipping, can be substantial.[6] During this period, patients with aggressive diseases may experience progression, sometimes to the point where they are no longer eligible for infusion or the CAR T-cell product cannot be successfully manufactured from their heavily pretreated T-cells.[6] This highlights a critical unmet need for more rapid, reliable, and potentially decentralized manufacturing processes, or the advancement of "off-the-shelf" allogeneic CAR T-cell products that do not rely on the patient's own cells.

Lymphodepleting Chemotherapy: Rationale and Regimens

Several days prior to the infusion of the engineered CAR T-cells, patients typically undergo a conditioning regimen with lymphodepleting chemotherapy.[2] The most common regimen combines fludarabine and cyclophosphamide (often abbreviated as Flu/Cy).

The primary rationale for lymphodepletion is to create a more receptive in vivo environment for the incoming CAR T-cells, thereby enhancing their engraftment, expansion, persistence, and anti-tumor activity.[33] This is achieved through several mechanisms:

• Depletion of Endogenous Lymphocytes: This reduces competition for essential homeostatic cytokines, such as IL-7 and IL-15, which are crucial for T-cell survival and proliferation. It also creates "space" within the lymphoid compartments for the CAR T-cells to engraft and expand.[33]
• Reduction of Immunosuppressive Cells: Lymphodepletion can deplete regulatory T-cells (Tregs) and other immune cells that might otherwise suppress the activity of the infused CAR T-cells.[33]
• Modulation of the Tumor Microenvironment: Chemotherapy can induce an inflammatory state and potentially reduce tumor burden, making the tumor more susceptible to CAR T-cell attack.[33]

Effective lymphodepletion is widely considered a critical factor for the success of CAR T-cell therapy.[33] While Flu/Cy is standard, alternative regimens, such as bendamustine in combination with fludarabine, have been explored, particularly for patients who may not tolerate standard Flu/Cy.[34] However, the necessity of lymphodepleting chemotherapy adds another layer of potential toxicity and physiological stress for patients, many of whom have already undergone multiple prior lines of therapy. This conditioning phase can lead to myelosuppression and increased infection risk, further complicating the management of these often frail patients and underscoring that CAR T-cell therapy outcomes are dependent on the entire peritreatment regimen, not solely the engineered cells.

CART-19 Cell Infusion and Patient Monitoring

Once the lymphodepleting chemotherapy is complete and the patient is deemed ready, the cryopreserved CAR T-cell product is thawed at the bedside and administered as a single intravenous infusion.[2] The infusion process itself is relatively short, often lasting less than an hour.[6]

Following infusion, patients require intensive monitoring, typically in an inpatient setting, for at least the first 7 to 10 days.[2] This period is critical for detecting and managing acute toxicities, most notably CRS and ICANS. Patients are advised to remain in close proximity to the specialized treatment center for at least 4 weeks post-infusion to allow for continued monitoring and management of any delayed toxicities or complications.[27]

Role of Specialized Treatment Centers

The administration of CART-19 therapy is a highly specialized process that is restricted to certified treatment centers.[27] These centers must possess the necessary infrastructure, multidisciplinary expertise, and protocols to manage all aspects of CART-19 therapy, including:

• Patient evaluation and selection.
• Coordination of leukapheresis and CAR T-cell manufacturing logistics.
• Administration of lymphodepleting chemotherapy and the CAR T-cell product.
• Acute and long-term monitoring for and management of complex toxicities, particularly CRS and ICANS. This includes having immediate access to interventions such as tocilizumab and intensive care unit (ICU) support.[36]
• Adherence to Risk Evaluation and Mitigation Strategies (REMS) mandated by regulatory authorities for most approved products.[27]

The requirement for such specialized centers, while essential for patient safety and optimal outcomes, inherently creates challenges related to patient access. Geographic distance, the financial burden of travel and lodging for extended periods, and caregiver requirements can limit the ability of some eligible patients to receive these potentially life-saving therapies.[40] This concentration of expertise and resources contributes to disparities in care and underscores the need for strategies to improve broader and more equitable access to CART-19 therapies.

4. Approved CART-19 Therapies: Clinical Efficacy and Indications

The therapeutic landscape for B-cell malignancies has been significantly reshaped by the regulatory approval of several CART-19 products. These therapies, developed by various pharmaceutical companies, often in collaboration with academic institutions, have demonstrated remarkable efficacy in heavily pretreated patient populations. Each approved product has a unique profile based on its CAR construct, manufacturing process, and the specific patient populations for which it is indicated.

Overview of FDA and EMA Approved Products, Developers, and Regulatory Designations

As of early 2025, several CART-19 therapies have received marketing authorization from the FDA and/or the EMA. These include:

• Tisagenlecleucel (Kymriah®): Developed by Novartis in pioneering collaboration with the University of Pennsylvania, tisagenlecleucel utilizes a CAR construct incorporating a 4-1BB costimulatory domain.[1]
• FDA Approvals:
• Relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric and young adult patients (up to 25 years of age), either refractory to treatment, in second or later relapse, or relapsed post-transplant (August 2017; this was the first CAR T-cell therapy approval globally).[1]
• R/r diffuse large B-cell lymphoma (DLBCL) in adult patients after two or more lines of systemic therapy, including DLBCL not otherwise specified (NOS), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (May 2018).[5]
• R/r follicular lymphoma (FL) in adult patients after two or more lines of systemic therapy (May 2022).[5]
• EMA Approvals:
• Pediatric and young adult patients (up to 25 years) with B-cell ALL that is refractory, in relapse post-transplant, or in second or later relapse (August 2018).[3]
• Adult patients with r/r DLBCL after two or more lines of systemic therapy (August 2018).[3]
• Adult patients with r/r FL after two or more lines of systemic therapy.[10]
• Key Regulatory Designations: FDA Breakthrough Therapy designation, FDA Orphan Drug designation, EMA Priority Medicines (PRIME) scheme, EMA Orphan Medicinal Product designation.[51]
• Axicabtagene ciloleucel (Yescarta®): Developed by Kite Pharma, a Gilead Company, axicabtagene ciloleucel features a CAR with a CD28 costimulatory domain.[3]
• FDA Approvals:
• Adult patients with r/r large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including DLBCL NOS, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (October 2017).[5]
• Adult patients with LBCL that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy (April 2022).[8]
• Adult patients with r/r FL after two or more lines of systemic therapy (March 2021, accelerated approval).[8]
• EMA Approvals:
• Adult patients with r/r DLBCL and PMBCL, after two or more lines of systemic therapy (August 2018).[3]
• Adult patients with r/r FL after three or more lines of systemic therapy.[10]
• Key Regulatory Designations: FDA Breakthrough Therapy designation, FDA Orphan Drug designation, EMA PRIME scheme.[63]
• Brexucabtagene autoleucel (Tecartus®): Also developed by Kite Pharma, a Gilead Company, brexucabtagene autoleucel employs a CD28 costimulatory domain and utilizes the XLP™ manufacturing process, which includes T-cell enrichment.[3]
• FDA Approvals:
• Adult patients with r/r mantle cell lymphoma (MCL) (July 2020, accelerated approval).[5]
• Adult patients (18 years and older) with r/r B-cell precursor ALL (October 2021).[5]
• EMA Approvals:
• Adult patients with r/r MCL (December 2020).[3]
• Adult patients (26 years and older) with r/r B-cell precursor ALL (December 2021).[3]
• Key Regulatory Designations: FDA Breakthrough Therapy designation, FDA Orphan Drug designation, FDA Priority Review, EMA PRIME scheme, EMA Orphan Medicinal Product designation.[36]
• Lisocabtagene maraleucel (Breyanzi®): Developed by Juno Therapeutics, a Bristol Myers Squibb Company, lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy with a 4-1BB costimulatory domain, administered as a defined composition of CD8+ and CD4+ CAR T-cells.[3]
• FDA Approvals:
• Adult patients with r/r LBCL after two or more lines of systemic therapy, including DLBCL NOS, high-grade B-cell lymphoma, PMBCL, and FL grade 3B (February 2021).[5]
• Adult patients with LBCL refractory to first-line chemoimmunotherapy or relapsing within 12 months of first-line chemoimmunotherapy; or relapsed/refractory after first-line chemoimmunotherapy and not eligible for hematopoietic stem cell transplant (HSCT) (June 2022).[8]
• Adult patients with r/r FL after two or more lines of systemic therapy (May 2024, accelerated approval).[47]
• Adult patients with r/r chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor (March 2024, accelerated approval).[47]
• Adult patients with r/r MCL who have received at least two prior lines of therapy, including a BTK inhibitor (May 2024).[81]
• EMA Approvals:
• Adult patients with r/r DLBCL, high-grade B-cell lymphoma, PMBCL, and FL grade 3B, who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy (April 2022).[3]
• Adult patients with r/r FL after at least two lines of systemic therapy (CHMP positive opinion January 2025, EC approval February 2025).[47]
• Key Regulatory Designations: FDA Priority Review, FDA Breakthrough Therapy designation, FDA Orphan Drug designation, FDA Regenerative Medicine Advanced Therapy (RMAT) designation.[81]
• Obecabtagene autoleucel (Aucatzyl®): Developed by Autolus Therapeutics, obe-cel is a CD19-directed CAR T-cell therapy designed with a fast target binding off-rate to potentially reduce toxicity and improve persistence.[83]
• FDA Approval:
• Adult patients with r/r B-cell precursor ALL (November 2024).[83]
• EMA Approval:
• CHMP positive opinion for conditional marketing authorisation for adult patients (26 years and older) with r/r B-cell precursor ALL (May 2025).[98]
• MHRA (UK) Approval:
• Conditional marketing authorisation for adult patients (≥18 years) with r/r B-cell precursor ALL (April 2025).[102]
• Key Regulatory Designations: EMA PRIME scheme, EMA Orphan Medicinal Product designation.[98]

A summary of these approved CART-19 products is provided in Table 1.

Table 1: Approved CART-19 Products and Key Characteristics

Product Name (Generic, Brand)	Developer(s)	Target Antigen	Costimulatory Domain(s)	Select FDA Approved Indications (Patient Population, Year)	Select EMA Approved Indications (Patient Population, Year)	Key Regulatory Designations (FDA/EMA)
Tisagenlecleucel (Kymriah®)	Novartis/Univ. of Pennsylvania	CD19	4-1BB	r/r B-ALL (ped/YA ≤25y, 2017); r/r DLBCL (adult ≥2L, 2018); r/r FL (adult ≥2L, 2022)	r/r B-ALL (ped/YA ≤25y, 2018); r/r DLBCL (adult ≥2L, 2018); r/r FL (adult ≥2L)	FDA BTD, Orphan; EMA PRIME, Orphan 1
Axicabtagene ciloleucel (Yescarta®)	Kite Pharma (Gilead)	CD19	CD28	r/r LBCL (adult ≥2L, 2017); r/r LBCL (adult 1L-refractory/early relapse, 2022); r/r FL (adult ≥2L, 2021)	r/r DLBCL/PMBCL (adult ≥2L, 2018); r/r FL (adult ≥3L)	FDA BTD, Orphan; EMA PRIME 3
Brexucabtagene autoleucel (Tecartus®)	Kite Pharma (Gilead)	CD19	CD28	r/r MCL (adult, 2020); r/r B-ALL (adult ≥18y, 2021)	r/r MCL (adult, 2020); r/r B-ALL (adult ≥26y, 2021)	FDA BTD, Orphan, Priority Review; EMA PRIME, Orphan 3
Lisocabtagene maraleucel (Breyanzi®)	Juno Therapeutics (BMS)	CD19	4-1BB	r/r LBCL (adult ≥2L, 2021); r/r LBCL (adult 2L, 2022); r/r FL (adult ≥2L, 2024); r/r CLL/SLL (adult ≥2L, 2024); r/r MCL (adult ≥2L, 2024)	r/r DLBCL/HGBCL/PMBCL/FL3B (adult 1L-refractory/early relapse, 2022); r/r FL (adult ≥2L, EC approval 2025)	FDA BTD, Orphan, Priority Review, RMAT; EMA PRIME 3
Obecabtagene autoleucel (Aucatzyl®)	Autolus Therapeutics	CD19	4-1BB (fast off-rate)	r/r B-ALL (adult, 2024)	r/r B-ALL (adult ≥26y, CHMP positive opinion May 2025)	EMA PRIME, Orphan; MHRA Conditional Auth. 83

Abbreviations: ALL: Acute Lymphoblastic Leukemia; BTD: Breakthrough Therapy Designation; CAR: Chimeric Antigen Receptor; CLL: Chronic Lymphocytic Leukemia; CR: Complete Remission; CRi: Complete Remission with incomplete hematologic recovery; DLBCL: Diffuse Large B-Cell Lymphoma; DOR: Duration of Response; EMA: European Medicines Agency; FDA: U.S. Food and Drug Administration; FL: Follicular Lymphoma; HGBCL: High-Grade B-Cell Lymphoma; HRQoL: Health-Related Quality of Life; LBCL: Large B-Cell Lymphoma; MCL: Mantle Cell Lymphoma; MRD: Minimal Residual Disease; ORR: Overall Response Rate; OS: Overall Survival; ped/YA: pediatric and young adult; PFS: Progression-Free Survival; PMBCL: Primary Mediastinal Large B-Cell Lymphoma; PRIME: PRIority MEdicines; PRO: Patient-Reported Outcome; QALY: Quality-Adjusted Life Year; r/r: relapsed or refractory; RMAT: Regenerative Medicine Advanced Therapy; SLL: Small Lymphocytic Lymphoma; SOC: Standard of Care; ≥2L: after two or more prior lines of therapy.

Pivotal Clinical Trial Evidence and Real-World Data

The approvals of these CART-19 therapies were based on data from pivotal clinical trials demonstrating substantial efficacy in patients with limited treatment options. Real-world evidence (RWE) is also accumulating, generally supporting the findings from these registration studies.

• Tisagenlecleucel (Kymriah®):
• ELIANA Trial (NCT02435849) for pediatric/young adult r/r B-ALL: This global, single-arm Phase 2 study was pivotal for the initial approval of tisagenlecleucel. It demonstrated an overall remission rate (ORR), defined as complete remission (CR) or CR with incomplete hematologic recovery (CRi), of 81-82% within three months of infusion in heavily pretreated patients.[57] All patients achieving remission were also minimal residual disease (MRD)-negative by flow cytometry, a strong predictor of durable response and survival.[57] Long-term follow-up data reported a 5-year relapse-free survival (RFS) of 49% and a 5-year overall survival (OS) rate of 55%.[57] The safety profile was considered manageable, with cytokine release syndrome (CRS) occurring in 77% of patients (Grade 3/4 in 46-48%) and neurological events in 40% (Grade 3 in 13%).[112] Patient-reported outcomes (PROs) from ELIANA indicated improvements in health-related quality of life (HRQoL), as measured by PedsQL and EQ-5D VAS, by month 3 post-infusion among responding patients.[114] The achievement of MRD negativity in such a high proportion of responders is a critical efficacy marker, strongly correlating with the potential for long-term disease control.[57]
• JULIET Trial (NCT02445248) for adult r/r DLBCL: This global, single-arm Phase 2 trial was pivotal for the DLBCL indication. The ORR was 52-53%, with 39-40% of patients achieving a CR.[115] For patients who achieved a CR, the median duration of response (DOR) was not reached, indicating long-term remissions in a subset of patients.[115] The median progression-free survival (PFS) was 2.9 months for the overall population, and median OS was 11.1-12 months.[115] Real-world evidence has generally supported these findings, with one large study reporting an ORR of 59.5% and a CR rate of 44.5%, and suggesting a potentially improved safety profile compared to the pivotal trial.[115] PROs from the JULIET study demonstrated sustained and clinically meaningful improvements in HRQoL (FACT-Lym, EQ-5D-5L) at 12 and 18 months for responding patients, although some persistent symptoms like fatigue were noted.[53]
• ELARA Trial (NCT03568461) for adult r/r FL: This international, single-arm Phase 2 trial supported the FL indication. It showed an ORR of 86% and a CRR of 66-68%.[57] At a median follow-up of approximately 17 months (primary analysis), the estimated 24-month PFS was 57.4%, DOR was 66.4%, and OS was 87.7%.[119] The safety profile was manageable, with no Grade ≥3 CRS reported in the primary analysis and low rates of severe neurological events.[119]
• Axicabtagene ciloleucel (Yescarta®):
• ZUMA-1 Trial (NCT02348216) for adult r/r LBCL (≥2 prior lines): This pivotal Phase 1/2 multicenter, single-arm study led to the initial approval for LBCL. It reported an ORR of 83%, with 58% of patients achieving a CR.[17] Long-term follow-up (median 63.1 months) demonstrated durable responses in 31% of patients, a median OS of 25.8 months, and an estimated 5-year OS rate of 42.6%, suggesting curative potential in a subset of patients.[122] The safety profile was manageable with established protocols.[122]
• ZUMA-7 Trial (NCT03391466) for adult LBCL (2nd line, high-risk): This landmark Phase 3 randomized controlled trial compared axi-cel to standard-of-care (SOC) second-line therapy (salvage chemoimmunotherapy followed by high-dose therapy and autologous stem cell transplant in responders). Axi-cel demonstrated statistically significant and clinically meaningful superiority over SOC in event-free survival (EFS; median 8.3 months vs 2.0 months; HR 0.40), ORR (83% vs 50%), and subsequently OS (median not reached vs 31.1 months at a later follow-up).[8] The safety profile was consistent with previous studies. Subgroup analyses confirmed the benefit of axi-cel in elderly patients (≥65 years and ≥70 years) compared to SOC.[124] PROs in elderly patients from ZUMA-7 have also been reported.[126] The success of ZUMA-7 has been instrumental in shifting CART-19 therapy to earlier lines of treatment for high-risk LBCL.
• ZUMA-5 Trial (NCT03105336) for adult r/r indolent non-Hodgkin lymphoma (iNHL), including FL and marginal zone lymphoma (MZL) (≥2 prior lines): This Phase 2, multicenter, single-arm study showed high efficacy. For FL patients, the ORR was 94% with a CR rate of 79%. For MZL patients, the ORR was 77% with a CR rate of 65%. At a 5-year follow-up for the FL cohort, the median PFS was 57.3 months, and the 60-month OS rate was 69.0% overall (lymphoma-specific OS for FL was 83.4%).[66] These data underscore the potential for long-term disease control.
• Brexucabtagene autoleucel (Tecartus®):
• ZUMA-2 Trial (NCT02601313) for adult r/r MCL (post-BTKi): This pivotal Phase 2, single-arm study led to accelerated approval. It reported an ORR of 91-93%, with a CR rate of 67-68%.[32] At a median follow-up of 35.6 months, the median DOR was 28.2 months, and median PFS was 25.8 months.[133] The safety profile was manageable. Subgroup analyses showed consistent responses across high-risk subgroups [133], and real-world data in older patients (≥70 years) demonstrated comparable efficacy and safety.[135]
• ZUMA-3 Trial (NCT02614066) for adult r/r B-ALL: This pivotal Phase 1/2, single-arm study showed an ORR (CR/CRi) of 71-74%, with a CR rate of 56-63%.[32] The median OS was 25.4-25.6 months with over 3 years of follow-up, and 38.9 months for responders.[136] Subsequent allogeneic HSCT did not appear to improve survival outcomes among responders.[136] Real-world data have confirmed high MRD-negative CR rates.[140]
• Lisocabtagene maraleucel (Breyanzi®):
• TRANSCEND NHL 001 Trial (NCT02631044) for adult r/r LBCL (≥2 prior lines): This pivotal Phase 1 multicenter study reported an ORR of 73% and a CR rate of 53%.[8] At a 2-year follow-up, median DOR was 23.1 months, median PFS was 6.8 months, and median OS was 27.3 months.[142] The therapy demonstrated a manageable safety profile, with low rates of severe CRS (2%) and neurological events (10%).[142] Real-world data have shown comparable efficacy and safety.[144]
• TRANSFORM Trial (NCT03575351) for adult LBCL (2nd line, ASCT-eligible): This Phase 3 randomized trial compared liso-cel to SOC. Liso-cel showed superior EFS (median 10.1 vs 2.3 months), CR rate (66% vs 39%), and PFS (median 14.8 vs 5.7 months).[8] HRQoL, assessed using EORTC QLQ-C30 and FACT-Lym, was improved or maintained with liso-cel compared to SOC, with time to confirmed deterioration in global health status/QoL favoring liso-cel.[146]
• TRANSCEND CLL 004 Trial (NCT03331198) for adult r/r CLL/SLL (post BTKi & BCL2i): This Phase 1/2 single-arm study led to accelerated approval. In the primary efficacy analysis set (DL2), the CR/CRi rate was 18-20%, and the ORR was 43-44%.[89] The median DOR for those achieving CR/CRi was not reached in the primary analysis, with an overall median DOR of 35.3 months reported later.[92] The safety profile was manageable.
• TRANSCEND FL Trial (NCT04245839) for adult r/r FL (≥2 prior lines): This Phase 2 single-arm study reported high ORR (97.1%) and CR rates (94.2%) in patients treated in the third-line or later setting, with durable responses (75.7% DOR at 18 months).[47] Safety was consistent with other liso-cel trials.
• PILOT Study (NCT03483103) for adult LBCL (2nd line, ASCT-ineligible): Patient-reported outcomes from this Phase 2 study were presented at ASCO 2022.[149]
• Obecabtagene autoleucel (Aucatzyl®):
• FELIX Trial (NCT04404660) for adult r/r B-ALL: This Phase 1b/2 single-arm study was pivotal for its approvals. In the pivotal cohort (Cohort IIA, n=94), the ORR (CR/CRi) was 76.6-77%.[97] The median DOR was 21.2 months, and median EFS was 11.9 months.[99] Obe-cel demonstrated a favorable safety profile with low rates of severe CRS (2.4-3%) and ICANS (7.1-8%).[83] Subgroup analyses by age showed comparable efficacy and safety in older adults (≥55 years).[150] Achieving MRD negativity was associated with improved outcomes.[105]

The consistent achievement of MRD negativity across multiple CART-19 products and trials (e.g., Kymriah in ELIANA [57], Tecartus in ZUMA-3 [137], Aucatzyl in FELIX [105]) is a particularly important finding. MRD negativity signifies a profound depth of remission, extending beyond what can be detected by standard clinical or radiological assessments. This deep response is a strong predictor of durable remission and improved long-term survival, suggesting that MRD status should be a key endpoint in evaluating CAR T-cell efficacy and guiding post-treatment patient management.

Furthermore, the accumulation of real-world evidence (RWE) is vital for contextualizing the results from controlled clinical trials.[65] While RWE generally supports the efficacy and safety observed in pivotal studies, it also provides insights into the performance of these therapies in broader, more heterogeneous patient populations, including those who might have been ineligible for the original trials (e.g., due to comorbidities or performance status). These real-world data are crucial for refining patient selection criteria, optimizing toxicity management strategies, and understanding the long-term effectiveness and challenges of CART-19 therapies in routine clinical practice.

The expansion of CART-19 approvals into earlier lines of therapy, such as second-line treatment for high-risk LBCL (Yescarta based on ZUMA-7 [8]; Breyanzi based on TRANSFORM [8]), represents a significant evolution in the field. This shift is predicated on the hypothesis that administering these potent therapies earlier, when patients may have a lower tumor burden and healthier, less exhausted T-cells from fewer prior treatments [6], could lead to improved manufacturing success, better CAR T-cell engraftment and function, and ultimately, more durable responses and better long-term outcomes. This trend has substantial implications for the future standard of care in B-cell malignancies.

A comparative summary of efficacy data from pivotal trials is presented in Table 2.

Table 2: Comparative Efficacy of Approved CART-19 Therapies by Indication (Based on Pivotal Trial Data)

Indication	Product Name (Brand)	Pivotal Trial(s)	N (Evaluable)	ORR (%) (CR/CRi %)	Median DOR (months) (for CR/CRi if specified)	Median PFS (months)	Median OS (months)	Snippet(s)
r/r B-ALL (ped/YA)	Tisagenlecleucel (Kymriah®)	ELIANA	75	81-82 (CR/CRi)	NR (5-yr RFS 49%)	NR	5-yr OS 55%	57
r/r B-ALL (adult)	Brexucabtagene autoleucel (Tecartus®)	ZUMA-3	55 (Phase 2)	71 (CR 56%, CRi 15%)	12.8	11.6	18.2 (Responders: NR)	136
r/r B-ALL (adult)	Obecabtagene autoleucel (Aucatzyl®)	FELIX (Cohort 2A)	94	77 (CR 55%, CRi 21%)	21.2	11.9	15.6	97
r/r DLBCL/LBCL (adult, ≥2L)	Tisagenlecleucel (Kymriah®)	JULIET	115	53 (CR 39%)	NR (for CRs)	2.9	11.1	57
r/r LBCL (adult, ≥2L)	Axicabtagene ciloleucel (Yescarta®)	ZUMA-1	101	83 (CR 58%)	NR (for CRs)	5.9 (overall)	25.8 (5-yr OS 42.6%)	17
r/r LBCL (adult, ≥2L)	Lisocabtagene maraleucel (Breyanzi®)	TRANSCEND NHL 001	257	73 (CR 53%)	23.1	6.8	27.3	142
r/r LBCL (adult, 2L, high-risk)	Axicabtagene ciloleucel (Yescarta®)	ZUMA-7	170 (axi-cel arm)	83 (CR 65%)	39.6 (for CRs)	8.3	NR (HR 0.73 vs SOC)	64
r/r LBCL (adult, 2L, ASCT-eligible)	Lisocabtagene maraleucel (Breyanzi®)	TRANSFORM	92 (liso-cel arm)	86 (CR 66%)	NR	10.1	NR (HR 0.51 vs SOC)	85
r/r FL (adult, ≥2L)	Tisagenlecleucel (Kymriah®)	ELARA	94	86 (CR 68%)	NR (24m DOR 66.4%)	NR (24m PFS 57.4%)	NR (24m OS 87.7%)	57
r/r FL (adult, ≥2L)	Axicabtagene ciloleucel (Yescarta®)	ZUMA-5	81 (FL cohort)	91 (CR 60%)	NR (median F/U 17.5m)	NR (median F/U 17.5m)	NR (median F/U 17.5m)	69
r/r FL (adult, ≥2L)	Lisocabtagene maraleucel (Breyanzi®)	TRANSCEND FL	103 (3L+)	97.1 (CR 94.2%)	NR (18m DOR 75.7%)	NR (24m PFS 72.5%)	NR (24m OS 88.2%)	47
r/r MCL (adult, post-BTKi)	Brexucabtagene autoleucel (Tecartus®)	ZUMA-2	68	91 (CR 68%)	28.2	25.8	NR (3yr OS ~50%)	32
r/r CLL/SLL (adult, post BTKi & BCL2i)	Lisocabtagene maraleucel (Breyanzi®)	TRANSCEND CLL 004	50 (DL2, primary efficacy set)	44 (CR/CRi 20%)	NR (for CR/CRi)	NR	NR (median F/U 23.8m)	89

Abbreviations as in Table 1. Data represent primary or key follow-up analyses from pivotal/supportive trials. NR: Not Reached. HR: Hazard Ratio. F/U: Follow-up. Efficacy outcomes can vary based on specific patient populations and follow-up duration.

5. Safety Profile and Management of CART-19 Toxicities

While CART-19 therapies have demonstrated remarkable efficacy, they are associated with a unique and potentially severe spectrum of adverse events. Understanding, anticipating, and managing these toxicities are paramount for patient safety and successful treatment outcomes. The most prominent acute toxicities are Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).

Cytokine Release Syndrome (CRS)

CRS is a systemic inflammatory response that is the most common acute toxicity following CART-19 infusion.[16] It is triggered by the activation and rapid proliferation of the infused CAR T-cells, which leads to the release of large amounts of inflammatory cytokines, not only from the CAR T-cells themselves but also from other host immune cells like macrophages that are activated in response.[13] Key cytokines implicated include interleukin-6 (IL-6), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α).[16]

Clinical Manifestations: CRS can manifest with a wide range of symptoms, from mild, flu-like symptoms such as fever, fatigue, headache, rash, arthralgia, and myalgia, to severe, life-threatening conditions.[13] Severe CRS is characterized by high fever, hypotension (which can progress to shock requiring vasopressors), hypoxia (potentially leading to acute respiratory distress syndrome requiring mechanical ventilation), tachycardia, vascular leakage, disseminated intravascular coagulation, and multi-organ dysfunction affecting the liver, kidneys, and heart.[15] Laboratory abnormalities such as cytopenias, elevated C-reactive protein (CRP), ferritin, creatinine, and liver enzymes are common.[15] In some severe cases, CRS can resemble hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS).[15]

Incidence and Grading: CRS is observed with all approved CART-19 products, though the incidence and severity can vary.

• Tisagenlecleucel (Kymriah): In pediatric/young adult ALL (ELIANA trial), CRS occurred in 77% of patients, with Grade 3/4 CRS in 46-48%.[112] In adult DLBCL (JULIET trial), CRS occurred in 74% (Grade ≥3 in 23%).[46] The median time to onset is typically 3 days, with a median duration of 7-8 days.[45]
• Axicabtagene ciloleucel (Yescarta): In LBCL (ZUMA-1/ZUMA-7), CRS occurred in approximately 87-93% of patients, with Grade ≥3 CRS in 5-9%.[43] Median time to onset is around 2-3 days, and median duration is 7-9 days.[37]
• Brexucabtagene autoleucel (Tecartus): In MCL and adult ALL (ZUMA-2/ZUMA-3), CRS occurred in 89-92% of patients, with Grade ≥3 CRS in 6-26%.[39] Median time to onset is 3-5 days, with a median duration of 7-9 days.[152]
• Lisocabtagene maraleucel (Breyanzi): Across various lymphoma indications, CRS occurred in approximately 45-58% of patients, with Grade ≥3 CRS in 1-3.2%.[80] Median time to onset is typically 5-6 days, with a median duration of 5 days.[80]
• Obecabtagene autoleucel (Aucatzyl): In adult ALL (FELIX trial), CRS occurred in 68.5-75% of patients, with Grade ≥3 CRS in 2.4-3%.[100] Median time to onset was 8 days, with a median duration of 5 days.[100] Standardized grading criteria, such as the American Society for Transplantation and Cellular Therapy (ASTCT) consensus criteria or the Lee criteria, are used to assess CRS severity and guide management.[15]

Management: Prompt recognition and intervention are crucial. Management strategies are guided by CRS grade:

• Supportive care (antipyretics, fluids, oxygen) is used for mild CRS.
• Tocilizumab, an IL-6 receptor antagonist, is the primary pharmacologic intervention for moderate (Grade 2) to severe (Grade ≥3) CRS.[13] It should be administered promptly when indicated.
• Corticosteroids (e.g., dexamethasone, methylprednisolone) are used for CRS refractory to tocilizumab or for life-threatening CRS, often in conjunction with tocilizumab.[16]
• Intensive care unit (ICU) support, including vasopressors and mechanical ventilation, may be required for severe cases.[113]

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

ICANS is another common and potentially severe toxicity associated with CART-19 therapy, which can occur concurrently with CRS, after CRS resolution, or in the absence of CRS.[14]

Pathophysiology: The exact mechanisms of ICANS are not fully elucidated but are thought to involve endothelial activation, disruption of the blood-brain barrier, and inflammatory cytokine effects within the central nervous system (CNS). Direct CAR T-cell trafficking into the CNS may also play a role.[14]

Clinical Manifestations: ICANS presents with a diverse range of neurological symptoms, including headache, confusion, delirium, agitation, hallucinations, expressive aphasia or word-finding difficulties (dysgraphia), tremors, ataxia, motor weakness, cranial nerve palsies, seizures, and altered levels of consciousness ranging from somnolence to coma.[13] In rare cases, life-threatening cerebral edema can occur.[157]

Incidence and Grading: The incidence and severity of ICANS vary among different CAR T-cell products and patient populations.

• Tisagenlecleucel (Kymriah): In ALL, neurological events occurred in 40% (Grade 3 in 13%).[113] In DLBCL, common neurological toxicities included headache (21%), encephalopathy (16%), delirium (5%).[46]
• Axicabtagene ciloleucel (Yescarta): In LBCL, ICANS occurred in approximately 50-78% of patients, with Grade ≥3 ICANS in 22-27%.[43]
• Brexucabtagene autoleucel (Tecartus): In MCL and adult ALL, ICANS occurred in 60-87% of patients, with Grade ≥3 ICANS in 21-35%.[39]
• Lisocabtagene maraleucel (Breyanzi): In LBCL, neurological toxicities occurred in 20-35%, with Grade ≥3 in 5-12%.[82]
• Obecabtagene autoleucel (Aucatzyl): In adult ALL, ICANS occurred in 23-38%, with Grade ≥3 in 7-12%.[100] The Immune Effector Cell-Associated Encephalopathy (ICE) score is a standardized tool used for grading ICANS severity, in conjunction with ASTCT criteria.[152] Median time to onset is typically 4-10 days post-infusion, and symptoms usually resolve, but can be prolonged in some cases.[37]

Management:

• Supportive care and neurological monitoring are essential.
• Corticosteroids are the mainstay of treatment for Grade ≥2 ICANS.[16]
• Tocilizumab is generally not considered effective for ICANS, as IL-6 is not thought to be the primary mediator of this toxicity, although it may be used if CRS is concurrent.[16]
• Antiepileptic drug prophylaxis (e.g., levetiracetam) is often administered, especially with products associated with higher ICANS rates.[152]
• For severe or refractory ICANS, higher doses of corticosteroids or other immunosuppressive agents may be considered.

The distinct and potentially severe toxicity profiles of CART-19 therapies, particularly CRS and ICANS, have profoundly influenced their clinical application. This has necessitated the development of specialized toxicity management algorithms and Risk Evaluation and Mitigation Strategies (REMS) programs for most approved products.[27] These programs mandate that CAR T-cell therapy be administered in certified healthcare facilities equipped with the expertise and resources (including immediate access to tocilizumab) to manage these complex adverse events. This specialized care requirement, while crucial for patient safety, also contributes to the logistical and access challenges associated with these therapies. The recent approval of Aucatzyl without a REMS requirement is a notable development, possibly reflecting a perceived more manageable safety profile or evolving regulatory perspectives [96], though it still carries boxed warnings for CRS and ICANS.[100]

Hematologic Toxicities and B-Cell Aplasia

Prolonged cytopenias, including neutropenia, thrombocytopenia, and anemia, are frequently observed following CART-19 therapy.[14] These cytopenias can be attributed to the lymphodepleting chemotherapy administered prior to CAR T-cell infusion, as well as direct effects of CAR T-cell activity and cytokine release. These hematologic toxicities can persist for weeks to months, increasing the risk of infections and bleeding, and often requiring supportive care such as growth factor administration (e.g., G-CSF) and blood product transfusions.[37]

A hallmark and expected "on-target, off-tumor" effect of CART-19 therapy is B-cell aplasia.[16] Because CD19 is expressed on normal B-cells, the CAR T-cells eliminate these along with the malignant B-cells. B-cell aplasia can persist for months or even years and serves as an indirect marker of CAR T-cell persistence and activity.[19] The primary consequence of prolonged B-cell aplasia is hypogammaglobulinemia, a deficiency in antibody levels, which significantly increases the patient's susceptibility to infections, particularly sinopulmonary infections caused by encapsulated bacteria.[19] Management of hypogammaglobulinemia typically involves regular monitoring of immunoglobulin levels and prophylactic administration of intravenous immunoglobulin (IVIG).[19] The need for long-term IVIG and ongoing infection surveillance represents a significant aspect of post-CART-19 care, contributing to the long-term management burden and healthcare costs associated with the therapy.

Infections

Patients undergoing CART-19 therapy are at a heightened risk of infections due to multiple factors, including the underlying malignancy, prior therapies, lymphodepleting chemotherapy, prolonged cytopenias (especially neutropenia), hypogammaglobulinemia secondary to B-cell aplasia, and the immunosuppressive effects of treatments used to manage CRS and ICANS (e.g., corticosteroids).[19]

Infections can be bacterial, viral (with respiratory viruses being common), or fungal, and can occur at various time points post-infusion.[21] The highest risk is often within the first month, but late infections can also occur, particularly in the context of persistent hypogammaglobulinemia.[21] Prophylactic antimicrobial agents (antibacterial, antiviral, antifungal, and Pneumocystis jirovecii pneumonia [PJP] prophylaxis) are commonly administered according to institutional guidelines and patient risk factors.[19] Vigilant monitoring for signs of infection and prompt initiation of empiric or targeted antimicrobial therapy are critical.

Long-Term Safety Considerations

Beyond the acute and subacute toxicities, long-term safety monitoring is essential for CART-19 recipients.

Secondary Malignancies: A significant long-term concern is the risk of developing secondary malignancies, particularly T-cell malignancies.31 In late 2023 and early 2024, the FDA initiated an investigation into reports of T-cell malignancies in patients who had received BCMA-directed or CD19-directed autologous CAR T-cell immunotherapies.163 This led to the requirement for class-wide boxed warnings on the labels of approved CAR T-cell products regarding this risk.31 While these events are considered rare, their occurrence, sometimes with the CAR transgene detected in the malignant T-cells, necessitates lifelong monitoring of patients for new malignancies.46 The exact causality—whether related to the CAR vector integration (insertional mutagenesis), chronic immune stimulation, patient predisposition, or prior therapies—is still under investigation.159 This emerging risk underscores the importance of long-term pharmacovigilance and further research into safer gene delivery and cell engineering techniques.164

Other long-term considerations include the potential for prolonged cytopenias, persistent hypogammaglobulinemia requiring ongoing IVIG, and the psychosocial impact of undergoing such intensive therapy and managing long-term health implications.

Risk Evaluation and Mitigation Strategies (REMS)

Due to the potential for severe and life-threatening toxicities like CRS and ICANS, the FDA has required REMS programs for most approved CART-19 therapies, including Kymriah, Yescarta, Tecartus, and Breyanzi.[27] The CARVYKTI REMS also exists for a BCMA-targeted CAR T.[42] These programs are designed to ensure that the benefits of the therapy outweigh its risks.

Key elements of these REMS programs typically include:

• Certification of Healthcare Facilities: Only hospitals and their associated clinics that are specially certified and have the necessary infrastructure and expertise to manage CAR T-cell toxicities are permitted to dispense and administer these therapies.[39]
• Prescriber Training: Healthcare providers involved in prescribing, dispensing, or administering CART-19 therapy must undergo specific training on the management of CRS and ICANS.[39]
• Availability of Tocilizumab: Certified facilities must have on-site, immediate access to tocilizumab for the treatment of CRS.[36]
• Patient Counseling and Monitoring: Ensuring patients are counseled on the risks and are appropriately monitored post-infusion.

Notably, Aucatzyl (obecabtagene autoleucel) was approved by the FDA without a REMS program requirement, though it does carry a boxed warning for CRS, ICANS, and secondary hematological malignancies.[96] This may reflect its specific safety profile observed in clinical trials or an evolution in regulatory approaches.

Table 3: Common and Serious Adverse Events Associated with CART-19 Therapy

Adverse Event Category	Specific Adverse Events	Typical Grade Range (Any Grade / Grade ≥3)	General Management Strategies	Snippet(s)
Cytokine Release Syndrome (CRS)	Fever, hypotension, hypoxia, tachycardia, fatigue, headache, myalgia, organ dysfunction	Very Common / Common to Uncommon (product-dependent)	Supportive care, tocilizumab, corticosteroids	13
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)	Encephalopathy, confusion, aphasia, delirium, seizures, tremor, headache, altered consciousness	Common / Common to Uncommon (product-dependent)	Supportive care, corticosteroids, anti-seizure prophylaxis	13
Hematologic Toxicities	Neutropenia, thrombocytopenia, anemia, febrile neutropenia, lymphopenia, pancytopenia	Very Common / Common to Very Common	Transfusions, growth factors (G-CSF), infection prophylaxis	14
B-Cell Aplasia & Hypogammaglobulinemia	Depletion of normal B-cells, low immunoglobulin levels	Expected / Common (hypogammaglobulinemia)	IVIG replacement, infection monitoring	16
Infections	Bacterial, viral, fungal infections	Common / Uncommon to Common (severe)	Antimicrobial prophylaxis and treatment	21
Long-Term Risks	Secondary T-cell malignancies, prolonged cytopenias	Rare (T-cell malignancies) / Uncommon (prolonged cytopenias)	Lifelong monitoring, supportive care	45

6. Patient-Reported Outcomes and Quality of Life with CART-19 Therapy

Beyond objective clinical endpoints such as response rates and survival, understanding the impact of CART-19 therapy on patients' health-related quality of life (HRQoL) and their subjective experiences is crucial for a holistic assessment of therapeutic value. The collection of patient-reported outcomes (PROs) is increasingly recognized as an integral component of evaluating novel cancer therapies, including CART-19.

Impact of CART-19 Therapy on Patient Well-being and Functional Status

Patients eligible for CART-19 therapy typically present with relapsed or refractory B-cell malignancies and have often endured multiple prior lines of treatment. Consequently, their baseline HRQoL is frequently compromised by disease symptoms, the cumulative effects of previous therapies, and the psychological burden of their diagnosis.[53] The CART-19 treatment process itself, including lymphodepleting chemotherapy and the potential for acute toxicities like CRS and ICANS, can lead to a temporary decline in HRQoL and functional status during the initial post-infusion period.[158]

However, for patients who achieve a durable remission following CART-19 therapy, there is substantial potential for significant and sustained improvements in HRQoL. Relief from disease-related symptoms, coupled with the cessation of ongoing cancer treatments, can lead to enhancements in physical well-being, emotional status, social functioning, and overall quality of life.[53] Nevertheless, a subset of patients may experience persistent symptoms such as fatigue or cognitive difficulties even after successful cancer treatment, underscoring the need for long-term survivorship care that addresses these ongoing issues.[53] The intensive nature of CAR T-cell therapy, including hospitalization, frequent monitoring, and the need to stay near the treatment center, can also impose a considerable burden on patients and their caregivers.[158]

Summary of HRQoL Data from Clinical Trials

Several pivotal clinical trials of approved CART-19 products have incorporated PROs and HRQoL assessments as secondary or exploratory endpoints.

• Tisagenlecleucel (Kymriah®):
• In the ELIANA trial (pediatric/young adult B-ALL), responding patients reported clinically meaningful improvements in HRQoL, as measured by the Pediatric Quality of Life Inventory (PedsQL) and the European Quality of Life-5 Dimensions (EQ-5D) visual analogue scale (VAS), by month 3 post-infusion.[114] These findings suggest a favorable benefit-risk profile when considering the patient's perspective alongside clinical efficacy and safety.
• In the JULIET trial (adult r/r DLBCL), patients who achieved a clinical response demonstrated sustained and clinically meaningful improvements in HRQoL. Assessments using the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and EQ-5D-5L showed improvements at 12 and 18 months post-infusion.[53] While overall HRQoL improved, some patients continued to experience persistent fatigue, psychological distress, or cognitive complaints.[53]
• Axicabtagene ciloleucel (Yescarta®):
• Patient-reported outcomes from the ZUMA-7 trial (2nd line LBCL in elderly patients) have been presented, indicating the importance of assessing HRQoL in this population.[126] An ASCO 2025 abstract also refers to a systematic literature review on clinical, economic, and humanistic outcomes in first-line high-risk LBCL, which may include QoL data related to Yescarta or similar therapies.[138]
• Lisocabtagene maraleucel (Breyanzi®):
• In the TRANSFORM trial (2nd line LBCL, ASCT-eligible), HRQoL was assessed using the EORTC QLQ-C30 and FACT-Lym. Patients in the liso-cel arm showed improvements or maintenance of HRQoL compared to those receiving standard of care. Notably, the time to confirmed deterioration in global health status/QoL favored the liso-cel arm.[146]
• The PILOT study (2nd line LBCL, ASCT-ineligible) also included PRO assessments, with results presented at ASCO 2022.[149]

The inclusion of PROs and HRQoL measures in these pivotal trials reflects a growing understanding that the patient's subjective experience and overall well-being are critical components in evaluating the true benefit of intensive and often costly cancer treatments like CART-19 therapy. These data provide valuable insights beyond traditional clinical endpoints, helping to inform treatment decisions, manage patient expectations, and guide the development of supportive care strategies to optimize long-term survivorship. While durable remissions can lead to significant QoL gains, the acute toxicity phase and the potential for lingering side effects highlight the ongoing need for comprehensive patient support throughout the CART-19 journey.

7. Overcoming Challenges: Resistance Mechanisms and Next-Generation Strategies

Despite the transformative success of CART-19 therapy in B-cell malignancies, a significant proportion of patients either do not respond (primary resistance) or relapse after an initial response (acquired resistance). Understanding the mechanisms underlying treatment failure is crucial for developing strategies to improve the efficacy and durability of CAR T-cell therapies.

Mechanisms of Resistance to CART-19 Therapy

Resistance to CART-19 therapy is multifactorial, involving tumor-intrinsic factors, CAR T-cell dysfunction, and the influence of the tumor microenvironment (TME).

• Antigen Escape (CD19 Loss or Downregulation): This is a primary mechanism of acquired resistance. Cancer cells can evade CAR T-cell recognition by losing or reducing the expression of the target CD19 antigen on their surface.[24] This can occur through various molecular mechanisms, including:
• Genetic mutations in the CD19 gene leading to frameshifts or premature stop codons.
• Alternative splicing of CD19 mRNA, resulting in protein variants that lack the CAR T-cell binding epitope.
• Epigenetic silencing of CD19 gene expression.
• Lineage switching, where the malignant B-cell differentiates into a myeloid or other lineage that does not express CD19. CD19-negative relapses have been reported in a substantial fraction of patients who relapse after CART-19 therapy, for instance, in approximately one-third to two-thirds of LBCL relapses.[174]
• T-Cell Exhaustion and Poor Persistence: Even if tumor cells continue to express CD19, the infused CAR T-cells may fail to mediate a durable anti-tumor response due to dysfunction or lack of persistence.[25]
• T-cell exhaustion is a state of T-cell dysfunction characterized by reduced effector functions (e.g., cytokine production, cytotoxicity), upregulation of inhibitory receptors (e.g., PD-1, LAG-3, TIM-3), and altered metabolic programming. It can be driven by chronic antigen stimulation from a high tumor burden or by the immunosuppressive TME.[25]
• Poor persistence refers to the inability of CAR T-cells to survive and maintain therapeutic levels in vivo over an extended period. Factors influencing persistence include the CAR construct design (e.g., costimulatory domain choice, with 4-1BB generally associated with longer persistence than CD28), the phenotype of the infused T-cells (e.g., a higher proportion of naïve or central memory T-cells in the apheresed product is associated with better expansion and persistence [177]), and host factors.
• Tumor Microenvironment (TME) Factors: The TME of many cancers, including some B-cell malignancies, can be highly immunosuppressive, creating a hostile environment for CAR T-cells.[23] Key TME-related resistance mechanisms include:
• Presence of immunosuppressive cells, such as regulatory T-cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), which can inhibit CAR T-cell function.[170]
• Expression of inhibitory checkpoint ligands (e.g., PD-L1) on tumor cells or other cells within the TME, which can bind to checkpoint receptors (e.g., PD-1) on CAR T-cells and dampen their activity.[170]
• Secretion of immunosuppressive cytokines (e.g., TGF-β, IL-10).[182]
• Physical barriers or metabolic challenges (e.g., hypoxia, nutrient deprivation) within the TME that can limit CAR T-cell infiltration, survival, and function.[177]
• Intrinsic Tumor Cell Resistance: Tumor cells themselves may possess or acquire mechanisms that make them resistant to CAR T-cell-mediated killing, even if the CAR T-cells are functional and can recognize the target antigen. This can involve defects in apoptotic signaling pathways within the tumor cell or upregulation of anti-apoptotic proteins.[170]
• Host and Product Factors: Patient-related factors such as high tumor burden at the time of infusion, certain prior therapies that may have compromised T-cell fitness, and elevated inflammatory markers (e.g., high LDH, CRP, ferritin) have been associated with poorer outcomes and increased risk of resistance.[180] The characteristics of the CAR T-cell product itself, including the proportion of different T-cell subsets (naïve, memory, effector) and the overall "health" or proliferative capacity of the engineered cells, also play a crucial role.[29]

The interplay between antigen loss and T-cell dysfunction drives many CART-19 therapy failures. This necessitates multifaceted approaches that not only enhance CAR T-cell potency and persistence but also anticipate and counteract tumor escape mechanisms.

Strategies to Enhance Efficacy and Durability

Numerous strategies are being investigated to overcome these resistance mechanisms and improve the outcomes of CART-19 and other CAR T-cell therapies:

• Dual-Targeting and Multi-Antigen Targeting CAR T-Cells: To combat antigen escape, CAR T-cells are being engineered to recognize more than one tumor antigen simultaneously. For B-cell malignancies, this often involves targeting CD19 along with another B-cell marker such as CD20 or CD22.[138]
• KITE-363, a dual-targeting CD19/CD20 CAR T-cell product from Kite/Gilead, is currently in Phase 1 clinical trials (NCT04989803) for r/r B-cell lymphomas, with data anticipated at ASCO and EHA in 2025.[138] This approach aims to prevent relapse due to CD19 loss by providing an alternative target (CD20).
• The concept extends to other diseases, such as ALLO-329 (Allogene Therapeutics), an allogeneic CD19/CD70 dual-targeting CAR T-cell therapy candidate for autoimmune diseases, which is expected to enter Phase 1 trials in mid-2025.[184]
• Allogeneic ("Off-the-Shelf") CAR T-Cell Therapies: These therapies utilize T-cells sourced from healthy donors rather than the patient. The potential advantages include immediate availability (overcoming manufacturing delays associated with autologous products), consistent product quality (as donor T-cells may be healthier), and potentially lower costs due to economies of scale.[184]
• A key challenge for allogeneic CAR T-cells is overcoming host-versus-graft disease (HVGD, where the host immune system rejects the CAR T-cells) and graft-versus-host disease (GVHD, where the allogeneic T-cells attack host tissues). Gene editing technologies like CRISPR/Cas9 are employed to disrupt genes responsible for TCR expression (to prevent GVHD) and HLA expression (to reduce immunogenicity and host rejection).[184]
• Cemacabtagene ansegedleucel (cema-cel, formerly ALLO-501A), an allogeneic anti-CD19 CAR T-cell product, has shown promising results in r/r LBCL in the ALPHA2/ALPHA trials (NCT04416984, NCT03939026). It demonstrated an ORR of 58% and a CR rate of 42%, with a median DOR in CR patients of 23.1 months. The safety profile was manageable, with no GVHD or severe ICANS reported when used with an anti-CD52 antibody (ALLO-647) as part of the lymphodepletion regimen to prevent CAR T-cell rejection.[186]
• BRL-303, another allogeneic CD19 CAR T-cell product, has shown promising early results in patients with refractory systemic lupus erythematosus (SLE) in an investigator-initiated trial (NCT05988216).[191] The development of allogeneic CAR T-cells represents a potential paradigm shift, moving away from highly individualized autologous therapies towards more readily accessible, standardized treatments. However, optimizing the balance between efficacy, persistence, and managing alloreactivity remains an active area of research.
• Safety-Engineered CAR T-Cells and Other Innovations:
• "Armored" CARs and TRUCKs (T-cells Redirected for Universal Cytokine-mediated Killing): These are fourth-generation CAR T-cells engineered to secrete pro-inflammatory cytokines (e.g., IL-12, IL-15, IL-18) or other immune-modulating molecules directly into the tumor microenvironment.[23] This strategy aims to counteract TME immunosuppression, enhance CAR T-cell proliferation and function, and recruit other host immune cells to the anti-tumor effort. For instance, huCART19-IL18, a CAR T-cell product secreting IL-18, has shown high response rates (ORR 81%, CR 52%) in heavily pretreated lymphoma patients, including those who had previously failed other CAR T-cell therapies.[24]
• Improved CAR Designs: Ongoing research focuses on optimizing various components of the CAR construct to enhance performance and safety. This includes:
• Modifying the scFv to alter antigen binding affinity or target novel epitopes.
• Engineering the hinge and transmembrane domains for optimal CAR expression and signaling.
• Exploring novel costimulatory domains or combinations to fine-tune T-cell activation, persistence, and differentiation (e.g., aiming for more memory-like phenotypes less prone to exhaustion).
• Incorporating "fast off-rate" binding domains, as seen with obecabtagene autoleucel, which may reduce tonic signaling and excessive T-cell activation, potentially leading to lower toxicity and improved persistence.[100]
• Combination Therapies: Combining CAR T-cells with other therapeutic modalities is a promising approach to overcome resistance. This includes combinations with:
• Immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies) to counteract T-cell exhaustion within the TME.[170]
• Epigenetic modulators (e.g., DNA methyltransferase inhibitors, histone deacetylase inhibitors) to potentially re-sensitize tumor cells to CAR T-cell attack by upregulating target antigen expression or altering the TME.[170]
• Other targeted agents or chemotherapy.
• Manufacturing Enhancements: Efforts are ongoing to improve CAR T-cell manufacturing processes, such as shortening the "vein-to-vein" time (e.g., a 3-day manufacturing process for huCART19-IL18 [25]) and optimizing T-cell culture conditions to yield products with more favorable characteristics (e.g., higher proportion of memory T-cells).
• Strategies to Mitigate Toxicity: Beyond optimizing CAR design (like obe-cel's fast off-rate), research continues into novel strategies to manage or prevent CRS and ICANS. This includes prophylactic measures, alternative cytokine blockade, and engineering CAR T-cells with safety switches or inducible suicide genes that allow for their conditional depletion if severe toxicity occurs. The use of mRNA-based CAR transfection for transient CAR expression and non-integrating viral vectors are also being explored as means to potentially improve safety profiles by limiting long-term CAR expression or insertional mutagenesis risks.[164]

The iterative engineering of CAR T-cells, from first-generation constructs to the sophisticated multi-component designs of today (including armored CARs and those with novel costimulatory domains), reflects a continuous effort to enhance T-cell effector function, promote persistence, and enable these cells to overcome the formidable challenges posed by the tumor and its microenvironment. This evolution is critical for extending the benefits of CAR T-cell therapy to a broader range of malignancies and improving outcomes for patients who currently experience resistance.

8. Health Economics, Market Access, and Equity

The advent of CART-19 therapies, while heralding a new era of treatment for B-cell malignancies, has also introduced significant economic and access challenges. The high cost of these personalized treatments, coupled with the complex logistics of their administration, necessitates careful consideration of their cost-effectiveness and the equitable distribution of their benefits.

Cost-Effectiveness Analyses and Value Frameworks for CART-19 Therapies

CART-19 therapies are associated with substantial upfront costs, often exceeding $400,000 USD per patient for the drug product alone, before accounting for hospitalization, toxicity management, and other ancillary care expenses.[195] This price point has spurred numerous cost-effectiveness analyses (CEAs) to evaluate their value relative to existing standard-of-care (SOC) treatments, particularly within different healthcare systems and for specific patient populations.

• Axicabtagene ciloleucel (Yescarta®): In the context of second-line (2L) treatment for r/r LBCL, an analysis based on the ZUMA-7 trial data from a Canadian healthcare perspective found axi-cel to be cost-effective compared to SOC. The incremental cost-effectiveness ratio (ICER) was estimated at $103,810 per quality-adjusted life year (QALY) gained, which decreased to $78,555/QALY when accounting for the crossover of SOC patients to subsequent cellular therapy.[198] An abstract for ASCO 2025 indicates a forthcoming presentation on the cost-effectiveness of real-world Yescarta use in 2L LBCL.[138]
• Lisocabtagene maraleucel (Breyanzi®): For patients with third-line or later (3L+) follicular lymphoma (FL), liso-cel was found to have a higher total cost compared to mosunetuzumab. However, it offered increased survival and reduced "time toxicity" (time spent receiving care or managing side effects), resulting in a lower cost per median PFS month ($11,650 for liso-cel vs $18,180 for mosunetuzumab).[199]
• Brexucabtagene autoleucel (Tecartus®): Several CEA studies have suggested that brexu-cel is cost-effective for r/r ALL and r/r MCL, particularly when compared against alternatives like blinatumomab, inotuzumab ozogamicin, or standard chemotherapy. These favorable ICERs are largely driven by the significant improvements in survival observed with brexu-cel.[200]

These analyses highlight that while the initial acquisition cost of CART-19 therapies is high, their potential for inducing durable remissions and extending survival can lead to favorable cost-effectiveness ratios in specific clinical contexts, especially when compared to the cumulative costs and limited efficacy of multiple lines of subsequent, less effective therapies.[92] Key drivers in these economic models include the drug acquisition cost, expenses related to managing acute toxicities (CRS and ICANS), hospitalization duration, the cost of subsequent treatments for non-responders or relapsing patients, and the gains in QALYs and overall survival. The long-term durability of response is a critical variable; if remissions are truly curative for a subset of patients, the upfront investment may be offset by savings from avoided future treatments and improved long-term health outcomes.

Market Access Considerations and Reimbursement Landscapes

Despite positive clinical data and favorable CEAs in some settings, securing market access and reimbursement for CART-19 therapies remains a complex challenge globally.[196] The high list prices create significant budgetary pressures for healthcare systems, whether they are publicly funded or insurance-based. Regulatory approval by agencies like the FDA or EMA does not automatically guarantee reimbursement or widespread patient access. For example, even with EMA approval, access to certain CAR T-cell therapies in the UK via the National Health Service (NHS) has faced hurdles related to funding and HTA evaluations.[205]

The specialized nature of CART-19 therapy delivery also impacts access. Treatment is restricted to certified centers with the expertise and infrastructure to manage the complex manufacturing logistics, administration, and acute toxicity management.[38] This concentration of services can limit geographical access for patients and create capacity constraints at treating institutions. To address these financial and logistical challenges, stakeholders are exploring innovative payment models, such as outcomes-based agreements or annuity payments, though widespread adoption of such models is still evolving.[197]

Addressing Disparities in Access to CART-19 Therapy

A growing body of evidence indicates significant disparities in access to CART-19 therapies.[48] These disparities are often linked to socioeconomic status, race and ethnicity, geographic location relative to certified treatment centers, and insurance coverage. Patients from underserved communities, racial and ethnic minorities, and those with lower socioeconomic status are frequently underrepresented in pivotal clinical trials and may face greater hurdles in accessing these advanced treatments in the real-world setting.[48]

Attrition rates—where eligible patients are referred for CAR T-cell therapy but do not ultimately receive it—can be substantial. Studies have shown that up to 41% of community-referred patients may not receive CAR T-cells, often due to disease progression or a decline in clinical status while awaiting the complex manufacturing and scheduling process.[48] Logistical burdens, such as the need for extended stays near the treatment center, caregiver support, and out-of-pocket expenses for travel and accommodation, disproportionately affect patients with limited financial or social resources.[40]

Addressing these disparities is critical to ensure that the transformative potential of CART-19 therapy is realized equitably. Strategies to mitigate these barriers include efforts to streamline referral pathways, reduce manufacturing times, explore decentralized or outpatient administration models where feasible and safe, provide financial and logistical support for patients and caregivers, and actively work to increase the diversity of participants in clinical trials.[48] The development of "off-the-shelf" allogeneic CAR T-cell products, by potentially simplifying manufacturing and improving immediate availability, could also play a role in enhancing access in the future.[184] Without proactive interventions, the high cost and complexity of CART-19 therapy risk exacerbating existing health inequalities.

Table 4: Summary of Select Cost-Effectiveness Findings for CART-19 Therapies

Product (Brand)	Indication	Comparator	Healthcare System/Country	Reported ICER / Economic Finding	Key Drivers	Snippet(s)
Axicabtagene ciloleucel (Yescarta®)	2L r/r LBCL	Standard of Care (SOC)	Canada	$103,810/QALY (reduced to $78,555/QALY adjusting for SOC crossover)	Improved QALYs and survival with axi-cel	198
Lisocabtagene maraleucel (Breyanzi®)	3L+ FL	Mosunetuzumab	Not specified (US context implied)	Higher total cost than mosunetuzumab, but lower cost per median PFS month ($11,650 vs $18,180) and reduced time toxicity	Increased survival, reduced infusion visits and productivity loss with liso-cel	199
Brexucabtagene autoleucel (Tecartus®)	r/r Adult ALL	Blinatumomab, Inotuzumab, Chemotherapy	US (hypothetical cohort)	Cost-effective vs. all comparators (e.g., ICER $20,843/QALY vs BLIN; $77,271/QALY vs INO; $93,768/QALY vs CHEMO at $150,000/QALY WTP)	Improved survival with brexu-cel	200
Brexucabtagene autoleucel (Tecartus®)	r/r MCL (post-BTKi)	Standard of Care (SoC)	UK	Cost-effective (details in source)	Durable responses and survival benefit	200

Abbreviations: 2L: Second-Line; 3L+: Third-Line or Later; ALL: Acute Lymphoblastic Leukemia; FL: Follicular Lymphoma; ICER: Incremental Cost-Effectiveness Ratio; LBCL: Large B-Cell Lymphoma; MCL: Mantle Cell Lymphoma; PFS: Progression-Free Survival; QALY: Quality-Adjusted Life Year; r/r: Relapsed or Refractory; SOC: Standard of Care; WTP: Willingness-to-Pay.

9. Future Perspectives: The Evolving Landscape of CART-19 Therapy

The field of CART-19 therapy is characterized by rapid evolution and ongoing innovation. While current approved products have transformed outcomes for many patients with B-cell malignancies, research continues at an accelerated pace to expand their applicability, enhance their efficacy, improve their safety profiles, and overcome existing limitations.

Expansion to New Indications

While CART-19 therapies are inherently limited to CD19-expressing diseases, the broader CAR T-cell technology platform is being actively investigated for a wide array of new indications.

• Solid Tumors: A major frontier for CAR T-cell therapy is the treatment of solid tumors. This presents significant challenges not typically encountered in hematologic malignancies, including identifying suitable tumor-specific or tumor-associated antigens, overcoming the highly immunosuppressive tumor microenvironment (TME), ensuring efficient CAR T-cell trafficking to and infiltration of tumor sites, and managing potential on-target, off-tumor toxicities against normal tissues expressing low levels of the target antigen.[23] Numerous CAR targets (e.g., B7-H3, EGFR, IL13Rα2, CLDN18.2) and engineering strategies are under investigation.[138] For example, BCB-276, a B7-H3 targeting CAR T-cell therapy, has received FDA Breakthrough Therapy and RMAT designations for pediatric diffuse intrinsic pontine glioma (DIPG) and is advancing in clinical trials.[165]
• Autoimmune Diseases: A particularly exciting and rapidly emerging application for CD19-targeted CAR T-cell therapy is in the treatment of autoimmune diseases. The rationale is that depleting CD19-expressing B-cells, including autoreactive B-cells and plasma cell precursors, can lead to an "immune reset" and ameliorate disease activity. Promising early clinical data are emerging in conditions such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), myasthenia gravis, and idiopathic inflammatory myopathies.[83]
• Allogene Therapeutics' ALLO-329, an allogeneic dual-targeting (CD19/CD70) CAR T-cell candidate, received FDA Fast Track Designations for SLE, inflammatory myopathies, and systemic sclerosis, with a Phase 1 trial (RESOLUTION) planned to initiate in mid-2025.[184]
• Bristol Myers Squibb is evaluating CD19 NEX-T (a liso-cel like construct) in Phase 1 trials for SLE (Breakfree-1), MS, and myasthenia gravis (Breakfree-2), with early data showing potential for treatment-free remission in some SLE patients.[83] The expansion into autoimmune diseases could dramatically broaden the impact of CAR T-cell technology beyond oncology, though it will also necessitate careful consideration of long-term safety, particularly regarding prolonged immunosuppression in non-malignant conditions.

Integration into Earlier Lines of Treatment

A clear trend in the clinical development of CART-19 therapies is their evaluation and approval in earlier lines of treatment for B-cell malignancies. Initially approved for heavily pretreated, relapsed/refractory settings, products like axicabtagene ciloleucel (Yescarta) and lisocabtagene maraleucel (Breyanzi) have now gained approvals for second-line treatment of high-risk LBCL, based on trials (ZUMA-7 and TRANSFORM, respectively) demonstrating superiority over standard chemoimmunotherapy followed by ASCT.[8]

The rationale for moving CAR T-cell therapy to earlier lines includes:

• Treating patients when their T-cells may be healthier and less exhausted from multiple prior therapies, potentially leading to better quality apheresis material and more robust CAR T-cell manufacturing and in vivo expansion/persistence.[6]
• Intervening when tumor burden might be lower and the disease less genetically complex or resistant.
• Potentially offering a curative-intent therapy sooner to patients with high-risk disease features who are unlikely to benefit from conventional salvage approaches. Ongoing and planned clinical trials are exploring CART-19 therapies as first-line treatment for certain high-risk B-cell lymphomas (e.g., ZUMA-23 trial for Yescarta [126]). This shift could fundamentally alter treatment algorithms if these therapies continue to demonstrate superior efficacy and manageable safety in earlier settings.

Key Insights from Recent and Upcoming Scientific Conferences (ASCO, EHA, AACR 2024-2025)

The field of CAR T-cell therapy is highly dynamic, with significant advancements regularly presented at major oncology and hematology conferences.

• ASCO 2025 (May 30 - June 3, 2025): Anticipated presentations include data on Kite's dual-target CD19/CD20 CAR T-cell therapy, KITE-363 (Abstract #7003).[138] Real-world outcomes and economic analyses for Yescarta in 2L LBCL (Abstract #PF1168, #PF1304) are also expected.[138] Patient-reported outcomes and quality of life data from various CAR T trials are often featured.[124] Late-breaking abstracts, often highlighting practice-changing data, are a key component of the ASCO meeting.[249]
• EHA 2025 (June 12-15, 2025): Presentations are expected on KITE-363 and other pipeline CAR T-cell therapies.[138] Real-world data, economic analyses, and updates on managing CAR T-cell toxicities are common themes.[138] The late-breaking abstract submission window is May 2-9, 2025, suggesting that very recent data will be presented.[253] An abstract (PB3495) on allogeneic CD19-targeted CAR T-therapy (BRL-303) for SLE has been published for EHA2025, showing promising early results.[191]
• AACR Annual Meeting 2025 (April 25-30, 2025): This meeting typically features more basic and translational research, including novel CAR designs, mechanisms of resistance, strategies to overcome T-cell exhaustion (e.g., armored CARs secreting IL-18), and manufacturing innovations.[256]

Recent Regulatory Milestones (May 2024 - May 2025)

The regulatory landscape for CAR T-cell therapies remains active:

• Obecabtagene autoleucel (Aucatzyl®): Received FDA approval for adult r/r B-ALL in November 2024.[83] The EMA's CHMP issued a positive opinion recommending conditional marketing authorisation for this indication in adult patients (≥26 years) in May 2025.[98] The UK's MHRA granted conditional marketing authorisation in April 2025.[102]
• Lisocabtagene maraleucel (Breyanzi®): Received FDA accelerated approval for r/r FL (after ≥2 prior lines) and r/r MCL (after ≥2 prior lines, including a BTKi) in May 2024.[81] The EMA's CHMP recommended approval for r/r FL (after ≥2 prior lines) in January 2025, with EC approval granted in February 2025.[47]
• Azercabtagene zapreleucel (azer-cel): This investigational allogeneic CD19-targeting CAR T-cell therapy received FDA Fast Track Designation for r/r DLBCL in March 2025.[160]
• Secondary T-cell Malignancies: A significant regulatory development has been the FDA's ongoing investigation into the risk of secondary T-cell malignancies following treatment with BCMA- and CD19-directed autologous CAR T-cell therapies, initiated in November 2023. This led to a class-wide requirement for boxed warnings on product labels in January 2024 regarding this risk.[163]

The rapid pace of clinical development, coupled with evolving regulatory frameworks, underscores the dynamism of the CAR T-cell field. The expansion into autoimmune diseases represents a particularly significant diversification, potentially opening up CAR T-cell technology to a much broader range of conditions beyond cancer. However, the consistent need for careful safety monitoring and management, highlighted by the investigations into secondary malignancies, emphasizes that while these therapies are powerful, their long-term implications are still being fully elucidated.

10. Conclusion

Recap of CART-19 Therapy's Transformative Impact

CART-19 therapy has unequivocally revolutionized the treatment landscape for patients with relapsed or refractory B-cell malignancies. By harnessing the power of a patient's own immune system through genetic engineering, these "living drugs" have demonstrated unprecedented rates of deep and durable remissions in diseases that were previously considered intractable.[1] Approved products such as Tisagenlecleucel (Kymriah®), Axicabtagene ciloleucel (Yescarta®), Brexucabtagene autoleucel (Tecartus®), Lisocabtagene maraleucel (Breyanzi®), and the more recently approved Obecabtagene autoleucel (Aucatzyl®) have become standard-of-care options in various settings of B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia, offering curative potential for a subset of patients.[8]

The journey from the initial concept of chimeric antigen receptors to globally approved therapies within a few decades exemplifies the accelerated pace of translational medicine in oncology.[5] The success of CART-19 is built upon a sophisticated understanding of immunology and genetic engineering, a complex personalized manufacturing process, and the development of specialized clinical management strategies for unique toxicities like CRS and ICANS.[2]

Outlook on Future Innovations and Clinical Integration

Despite its successes, the field of CART-19 therapy continues to face challenges and pursue further innovation. Ongoing research is intensely focused on:

• Improving Safety: Developing strategies to mitigate or prevent severe CRS and ICANS, potentially through novel CAR designs (e.g., fast off-rate binders like obe-cel [100]), safety switches, or optimized management protocols. The long-term risk of secondary malignancies also requires continued vigilance and research into safer vector technologies.[164]
• Overcoming Resistance: Addressing mechanisms of relapse, particularly antigen escape (CD19 loss) and T-cell exhaustion, through multi-antigen targeting CARs (e.g., CD19/CD20 dual CARs like KITE-363 [138]), armored CARs that modulate the tumor microenvironment (e.g., IL-18 secreting CARs [24]), and combination therapies.[168]
• Expanding Applicability:
• Moving into earlier lines of therapy for B-cell malignancies, where patient T-cells may be healthier and tumor burden lower, potentially improving outcomes as suggested by trials like ZUMA-7 and TRANSFORM.[8]
• Exploring novel indications beyond oncology, with particularly promising early results in autoimmune diseases like SLE, where B-cell depletion can lead to disease remission.[83]
• Developing "off-the-shelf" allogeneic CAR T-cell products derived from healthy donor T-cells to overcome the logistical and manufacturing challenges of autologous therapies, thereby increasing accessibility and reducing vein-to-vein time.[186]
• Addressing Economic and Access Challenges: The high cost and specialized delivery requirements of current CART-19 therapies pose significant hurdles to widespread and equitable access.[48] Future innovations in manufacturing, potential for outpatient administration [6], and evolving reimbursement models will be critical to ensuring that these transformative therapies can benefit all eligible patients.

The field of CART-19 therapy is a testament to the power of scientific innovation in oncology. As research continues to unravel the complexities of tumor immunology and CAR T-cell biology, further advancements are anticipated that will likely refine current approaches, expand therapeutic indications, and ultimately improve outcomes for an even broader range of patients. The ongoing dialogue between researchers, clinicians, regulatory agencies, payers, and patients will be essential in navigating the path forward for this dynamic and life-changing therapeutic modality.

References

1 PMC5699508

4 ASH Publications - Blood - CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS

8 PMC11514108

9 PMC11305028

10 PMC10094630

59 BioPharm International - EMA Recommends First CART-T Cell Therapies

44 FDA - Kymriah

50 Children's Hospital - Kymriah (tisagenlecleucel)

61 Gilead - Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan

62 NIH Tech Transfer - Yescarta Case Study

80 Bristol Myers Squibb - Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

81 Wikipedia - Lisocabtagene maraleucel

72 AdisInsight - Brexucabtagene autoleucel - Kite Pharma

73 Tecartus HCP - Tecartus

2 Dana-Farber - CAR T-Cell Therapy

3 Wikipedia - CAR T cell

260 Frontiers in Immunology - Editorial: CAR-T cells: The next generation

22 PMC6330382

162 Cancer.gov - NCI-2022-02972

14 Cancer.org - How CAR T-cell therapy works

13 Synapse Patsnap - What is the mechanism of tisagenlecleucel

261 Synapse Patsnap - What Does Tisagenlecleucel Do

17 DrugBank - Axicabtagene ciloleucel

67 PubChem - Axicabtagene Ciloleucel

111 Cancer.gov - Lisocabtagene Maraleucel

85 The Medical Letter - Breyanzi (Lisocabtagene Maraleucel) for Large B-Cell Lymphoma

32 PMC10664098

74 OncologyTube - Brexucabtagene autoleucel

56 Drugs.com - Tisagenlecleucel

57 PMC10294746

58 Wikipedia - Tisagenlecleucel

60 EMA - Kymriah EPAR Product Information

17 DrugBank - Axicabtagene ciloleucel (DB13915)

69 JHOP Online - Yescarta First CAR T-Cell Therapy Approved for Follicular Lymphoma

71 EMA - Yescarta EPAR Product Information

67 PubChem - Axicabtagene Ciloleucel (Compound)

81 Wikipedia - Lisocabtagene maraleucel (Breyanzi)

89 Targeted Oncology - FDA Approves Liso-Cel in Relapsed or Refractory CLL/SLL

93 ESMO - EMA Recommends Extension of Therapeutic Indications for Lisocabtagene maraleucel

87 Blood Cancers Today - CHMP Recommends Approval of Liso-Cel for Follicular Lymphoma

78 PA Health Wellness - Brexucabtagene autoleucel (Tecartus) Policy

39 Gilead - U.S. FDA Approves Kite's Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma

79 Wikipedia - Brexucabtagene autoleucel

130 Medscape - Tecartus (brexucabtagene autoleucel) Dosing, Indications, Interactions, Adverse Effects, and More

262 PMC10647582

95 Cancer.gov - CAR T-Cell Therapies for Adults and Children

263 PMC10964476

264 UCSD Health - Managed Access Program for Tisagenlecleucel (CTL019)

127 PMC9761215

70 FDA - FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma

265 Onclive - LV20.19 CAR T-cell Therapy Yields 100% ORR and Manageable Toxicity in R/R MCL

266 PMC10064560

90 Patient Power - CAR T Approval: What It Means for Patients With CLL

91 Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

112 South Carolina Blues - Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies

57 PMC10294746 - Real-world evidence of tisagenlecleucel in patients with relapsed or refractory diffuse large B-cell lymphoma: an updated systematic literature review

115 JITC - Real-world evidence of tisagenlecleucel for patients with relapsed or refractory diffuse large B-cell lymphoma/high-grade B-cell lymphoma: a CIBMTR subgroup analysis from the CCP

116 ASH Publications - Blood - Prediction of Poor Outcome after Tisagenlecleucel Infusion in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Using AI-Based Analysis of Pre-Infusion FDG PET/CT and Clinicopathological Parameters

119 ASH Publications - Blood - Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: 2-year follow-up of ELARA

120 Kymriah HCP - KYMRIAH® (tisagenlecleucel) Efficacy in r/r Follicular Lymphoma (FL)

68 PMC9427701

122 PMC10646788

123 Lymphoma Hub - Outcomes of subsequent therapies after 2L axi-cel or SOC in R/R LBCL: ZUMA-7 study

124 Cancer Network - Axicabtagene Ciloleucel Shows OS Improvement in Large B-Cell Lymphoma

128 Lymphoma Hub - ZUMA-5: 5-year follow-up analysis of axicabtagene ciloleucel in patients with R/R iNHL

129 PMC10934297

142 ASH Publications - Blood Advances - Two-year follow-up of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma in the TRANSCEND NHL 001 study

143 PubMed - Two-year follow-up of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma in the TRANSCEND NHL 001 study

267 ASCO Pubs - Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7)

86 OncLive - Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL

92 OncLive - Liso-Cel Prolongs Responses, PFS, and OS in Pretreated High-Risk R/R CLL

147 Clinical Options - TRANSCEND CLL 004: Lisocabtagene Maraleucel in R/R CLL/SLL

88 OncLive - Liso-cel Receives European Approval in Relapsed/Refractory Follicular Lymphoma

148 Blood Cancers Today - Phase II Data: Liso-Cel Overall, Complete Response Rates Favorable in Both MZL, Follicular Lymphoma

131 OncLive - ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups

132 Onc Nursing News - Brexu-Cel Yields High Response Rates in Relapsed/Refractory BTK-Naïve MCL

136 Lymphoblastic Hub - ZUMA-3 trial: 3-year follow-up analysis

137 ASCO Pubs - Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

14 Cancer.org - CAR T-cell Therapy Side Effects

37 CARTHope - Safety Profile of CAR T Therapy

15 JITC - Cytokine release syndrome

16 ASH Publications - Blood - Toxicities of chimeric antigen receptor T cells: recognition and management

157 PMC9445841 - Immune effector cell associated neurotoxicity syndrome in CAR-T cell therapy

156 PMC9445841

20 PMC8837681

19 NCBI Bookshelf - Management of B-Cell Aplasia and Hypogammaglobulinaemia After CD19/CD22 CAR-T Cell Therapy

21 Frontiers in Oncology - Infections after CAR T-cell therapy: A comprehensive review

161 Frontiers in Immunology - Case Report: Invasive fungal infection after anti-CD19 CAR-T cell therapy. Implication for antifungal prophylaxis

163 AACR - New Perspectives on the Risk of Secondary Cancers After CAR T-Cell Therapy

159 Frontiers in Oncology - Long-term complications after CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma: a comprehensive review

41 FDA - Risk Evaluation and Mitigation Strategies | REMS

42 CARVYKTI REMS - CARVYKTI REMS

45 Kymriah HCP - KYMRIAH® (tisagenlecleucel) Safety Profile in r/r ALL

46 Kymriah HCP - KYMRIAH® (tisagenlecleucel) Safety Profile in r/r DLBCL

153 OncLive - Dr. Lee on the Real-World Safety Profile of Axi-Cel in R/R LBCL

43 Yescarta HCP - YESCARTA® (axicabtagene ciloleucel) Safety Profile in 2L LBCL

144 PMC11993828

155 Cancer Network - Anakinra Ineffective in Preventing CRS/ICANS After Liso-cel in LBCL

152 EMCrit Project - IBCC: CAR-T cell therapy

154 PMC11532742

6 Novartis - The Process of CAR-T Cell Therapy

7 SU Support - CAR T manufacturing process & supply chain for cell therapies

33 PMC10770848

34 Multiple Myeloma Hub - Lymphodepletion optimization for CAR T-cell therapy

38 US Pharmacist - Outpatient CAR-T Therapy: Revolutionizing Cancer Treatment

40 ASCO Pubs - Sisyphus and CAR T Cells: Understanding and Overcoming Barriers to Access

27 Kymriah - How will I get KYMRIAH?

30 Drugs.com - How is Kymriah administered?

35 Yescarta HCP - YESCARTA® (axicabtagene ciloleucel) Manufacturing and Process

28 Yescarta - Receiving YESCARTA® (axicabtagene ciloleucel)

47 Bristol Myers Squibb - Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

31 Breyanzi - BREYANZI® (lisocabtagene maraleucel) Treatment Process

36 EMA - Tecartus EPAR

39 Gilead - U.S. FDA Approves Kite's Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma (2020)

5 PMC10225594

11 PMC7036015

3 Wikipedia - CAR T cell (Regulatory Approval Table)

12 Acta Haematologica Polonica - Chimeric antigen receptor T-cells (CAR-T) in treatment of B-cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphomas (NHL)

51 FDA Orphan Drug Designations - Kymriah for DLBCL

52 EMA - Kymriah (tisagenlecleucel)

63 Lymphoma News Today - Kite Seeks E.U. Approval for CAR T-Cell Therapy for 3 Lymphoma Subtypes (2017)

64 FDA - FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma (2022)

82 Oncology Practice Management - FDA Approves Breyanzi for Advanced Large B-Cell Lymphoma (2021)

94 Wikipedia - Regenerative medicine advanced therapy

75 Clinical Trials Arena - Tecartus (brexucabtagene autoleucel) for Mantle Cell Lymphoma

76 FDA - FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (2021)

268 EHA - 7th European CAR T-cell Meeting (Feb 2025)

269 OncoDaily - iwCAR-T 2025 Highlights

186 PubMed - Allogeneic CD19 CAR T-cell product cemacabtagene ansegedleucel (cema-cel) and its predecessor, ALLO-501, in CD19 CAR T-naïve patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)

187 ASH Publications - Blood Advances - Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies using Epstein-Barr virus–specific T cells

168 PMC11869864

179 Lyell Immunopharma - Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Platform at the 43rd Annual J.P. Morgan Healthcare Conference (Jan 2025)

270 ASH Publications - Blood Advances - Predicting CAR T-cell toxicity: insurance for CAR T therapy success

164 EMBO Molecular Medicine - Safe CAR-T: shedding light on CAR-related T-cell malignancies

169 ASH Publications - Blood Advances - Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma: current state of the art and future directions

194 PMC12036236

175 Blood Cancers Today - With More Experience, CAR T-cell Therapies Come Into Better Focus

176 PMC11646216

208 Cell & Gene - Cell & Gene Therapies In 2025 Will Represent A Continuation Of FDA’s Developments From 2024

108 Israeli Hospitals - CAR-T Updates 2025: Latest FDA-Approved Treatments and Advancements

271 Lymphoma Research Foundation - ASH 2024: Poor Outcomes Observed Following Disease Progression After CD19-Directed CAR T-Cell Therapy

272 NIH RePORTER - Next-generation CAR-NK cells targeting CD70 in B-NHL after CAR19 T-cell failure

188 ASCO Pubs - Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

273 Blood Cancers Today - ASH 2024: CAR-T Cell Therapy

274 ASH News Daily - Flash Forward: Blood Cancer Highlights and Insights From the 2024 ASH Annual Meeting & Exposition

252 EHA Library - CAR-T CELLS SPECIFIC TOXICITIES AS MAJOR DETERMINANTS OF NON-RELAPSE MORTALITY IN 932 LYMPHOMA PATIENTS. A CART-SIE REAL-LIFE STUDY (Abstract S282, EHA2025)

191 EHA Library - ALLOGENEIC CD19-TARGETED CAR-T THERAPY FOR REFRACTORY MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (Abstract PB3495, EHA2025)

96 Drugs.com - Aucatzyl FDA Approval History

97 OncLive - FDA Approves Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia (Nov 2024)

165 Targeted Oncology - Novel CAR T Therapy Earns FDA Breakthrough Status for Incurable Pediatric Brain Tumor (Apr/May 2025)

275 CGTLive - FDA Activity Recap April 2025 Features Major Approval in RDEB, Multiple Breakthrough Therapy Designations

109 EMA - New treatment for adults with acute lymphoblastic leukaemia (Aucatzyl, May 2025)

276 Aptitude Health - Most FDA and EMA Oncology Drug Approvals in Q1 2025 Were New Indications for Biologics and Biosimilars

249 Cancer Network - ASCO 2025: The Presentations That May Shift the Cancer Care Paradigm (May 2025)

250 Oncology Pipeline - ASCO 2025 Preview: Late-Breakers Focus (May 2025)

253 EHA - EHA2025 Late-Breaking Abstract Submission (Closed May 9, 2025)

254 EHA - EHA2025 Late-Breaking Abstract Submission Terms and Conditions

256 AACR - AACR Annual Meeting 2025: News and Highlights

257 AACR Blog - Unleashing the Power of CAR T Cells: Insights from Day 3 of AACR IO (Feb 2025)

98 EMA - Aucatzyl (obecabtagene autoleucel) - Opinion Adopted May 22, 2025

99 Cancer Network - Obe-cel Receives Positive CHMP Opinion for R/R B-Cell ALL (May 2025)

24 Penn Today - Enhanced CAR T cell therapy offers new strategy for lymphoma (May 2025)

25 ScienceDaily - Next-generation CAR T cell therapy works where other CAR T cell therapies have failed (May 2025)

187 ASH Publications - Blood Advances - Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies using Epstein-Barr virus–specific T cells (Feb 2025)

184 CRISPR Medicine News - Allogene's Dual-Acting CAR T Candidate ALLO-329 Gets FDA Green Light for Autoimmune Disease Trial (Jan 2025)

169 ASH Publications - Blood Advances - Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma: current state of the art and future directions (Feb 2025)

185 GlobeNewswire - Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329 (Apr 2025)

23 PMC11880241

209 CGTLive - FDA Activity Recap January 2025 Features CRL, Multiple Clinical Holds & More

138 Gilead - Gilead and Kite Announce Presentation of Transformative Data... at 2025 ASCO and EHA (May 2025)

191 EHA Library - ALLOGENEIC CD19-TARGETED CAR-T THERAPY FOR REFRACTORY MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (EHA2025 Abstract PB3495)

110 EMA - Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 May 2025

98 EMA - Aucatzyl (obecabtagene autoleucel) - CHMP Positive Opinion May 2025

100 Autolus Press Release - Autolus Therapeutics Provides Business Updates and 2025 Overview (Jan 2025)

101 Autolus Corporate Presentation - Q2 2025 Corporate Presentation (May 2025)

192 Frontiers in Immunology - Overcoming resistance to immune checkpoint inhibitors by combination therapy (May 2025)

277 Targeted Oncology - Strategies to Overcome CAR T Roadblocks in the Real-World Practice Setting (May 2025)

83 BioSpace - 5 CAR T-Cell Therapies with Autoimmune Readouts in 2025 (Feb 2025)

214 PMC11815715

195 PMC11700040

201 ASCO Pubs - Educational Book - Economic Challenges of CAR T-Cell Therapy

251 ASCO - Abstract Policies & Embargoes: Frequently Asked Questions (ASCO 2025)

253 EHA - EHA2025 Late-Breaking Abstract Submission (May 2025)

255 EHA - 7th European CAR T-cell Meeting Abstract Submission (Jan 2025)

212 Targeted Oncology - Novel CAR T Earns FDA RMAT Designation for Incurable Pediatric Brain Tumor (May 2025)

108 Israeli Hospitals - CAR-T Updates 2025: Latest FDA-Approved Treatments and Advancements (Jan 2025)

205 EMJ Reviews - COMy 2025: CAR T-Cell Therapy Access Gaps in Myeloma (May 2025)

278 Aptitude Health - Majority of New FDA and EMA Oncology Drug Approvals in Q4 2024 Were for Biologics and Biosimilars (May 2025)

279 PubMed - Hu19-CD828Z CAR T cells have diminished cytokine release and neurotoxicity while maintaining antitumor activity (Jan 2020, but foundational for later work)

280 ResearchGate - Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma (May 2025)

281 Novartis - CAR-T Cell Therapy and Beyond (Accessed May 2025)

282 BioSpace - Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Outlook 2025-2035 (July 2024, but forecasts into 2025)

138 Gilead Press Release - Gilead and Kite Announce Presentation of Transformative Data... at 2025 ASCO and EHA (May 2025)

167 Nasdaq - Gilead and Kite Announce Presentation of Transformative Data... at 2025 ASCO and EHA (May 2025)

47 Bristol Myers Squibb Press Release - Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma (Feb 2025)

230 Bristol Myers Squibb Press Release - Bristol Myers Squibb to Present Data at ASCO® 2025 (May 2025)

102 Autolus Press Release - Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel (May 2025)

283 Autolus Press Release - Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Annual Congress (May 2025)

215 Targeted Oncology - Hematology Experts Outline the Top Abstracts to Watch at the 2025 ASCO Annual Meeting (May 2025)

216 ASCO - ASCO Annual Meeting Abstracts (May 2025)

98 EMA - Aucatzyl (obecabtagene autoleucel) - CHMP Positive Opinion (May 2025)

110 EMA - Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 May 2025

284 NIH RePORTER - Immunologic Correlates of Outcomes After CAR T-Cell Therapy (Project end date Sep 2025)

258 DocWire News - Novel CAR T-Cell Therapy for Relapsed Refractory DLBCL Receives FDA Fast Track Designation (Mar 2025)

174 ASCO Pubs - KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL) (ASCO 2025 Abstract)

138 Gilead Press Release - Gilead and Kite Announce Presentation of Transformative Data... (May 2025, mentions KITE-363)

285 ASCO Pubs - Impact of COVID-19 infection on CAR-T therapy outcomes (ASCO 2025 Abstract)

158 Taylor & Francis Online - Patient experience with CAR-T cell therapy: a review of physical, psychological, and care delivery challenges (May 2025)

138 Gilead Press Release - Gilead and Kite Announce Presentation... (ASCO/EHA 2025 abstracts, includes HRQoL mention for NSCLC, but relevant for Gilead's oncology focus)

83 BioSpace - 5 CAR T-Cell Therapies with Autoimmune Readouts in 2025 (Feb 2025, mentions QoL)

29 PMC8214555 - Overcoming resistance to CAR T cell therapy (Review, relevant concepts)

170 Frontiers in Immunology - Overcoming resistance in CD19 CAR-T cell therapy for B-cell hematological malignancies (Review, relevant concepts)

183 Frontiers in Immunology - Predictive biomarkers for CD19-directed CAR-T therapy in lymphoma (Review, relevant concepts)

180 PMC11195421 - Functional drivers of resistance to anti-CD19 CAR-T cell therapy (May 2024, relevant concepts)

196 Frontiers in Medicine - The economic burden of CAR-T cell therapy: a systematic review (July 2024, relevant concepts)

197 Taylor & Francis Online - Critical success factors in chimeric antigen receptor T-cell therapy for multiple myeloma: a qualitative study (May 2025)

48 ASH Publications - Blood Advances - Receiving CAR T cells gets faster, but not for all: A call to address access barriers (Jan 2025)

49 ASH Publications - Blood Advances - Access barriers to anti-CD19+ CART therapy for NHL in a community-based network: A Sarah Cannon Transplant and Cellular Therapy Network Registry analysis (Jan 2025)

108 Israeli Hospitals - CAR-T Updates 2025: Latest FDA-Approved Treatments and Advancements (Jan 2025, general update)

259 Blood Cancers Today - FDA Issues Fast Track Designation for New CAR T-Cell Therapy for Relapsed Refractory DLBCL (Mar 2025)

286 MDPI - Real-World Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Third-Line Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Single-Center Study (Jan 2025)

26 MDPI - CAR-T Cell Therapy: Current Limitations and Potential Strategies in Solid Tumor Treatment (Feb 2025, general CAR T advancements)

217 Targeted Oncology - ASCO 2025 Preview: Practice-Changing Trials to Watch (May 2025, general ASCO preview)

210 Am J Med Case Rep - A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies (Feb 2025, general review)

114 PubMed - Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial (ELIANA PROs)

121 ASCO Pubs - Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial (ASCO 2021, but ELARA data relevant)

126 ASCO Pubs - Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7) (ASCO 2023 abstract, ZUMA-7 PROs)

53 ResearchGate - Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma (JULIET PROs, published 2020, but long-term data)

92 OncLive - Liso-Cel Prolongs Responses, PFS, and OS in Pretreated High-Risk R/R CLL (TRANSCEND CLL 004, May 2024)

146 PMC9713278 - Health-related quality of life with lisocabtagene maraleucel versus standard of care in second-line relapsed or refractory large B-cell lymphoma in the TRANSFORM study (Nov 2022)

140 PubMed - Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study (Jan 2025)

141 ASCO Post - Outcomes With Brexucabtagene Autoleucel as Standard Therapy for Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (Oct 2024, ZUMA-3 RWE)

102 Autolus Press Release - Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel (May 2025, FELIX data)

150 EHA Library - EFFICACY AND SAFETY OUTCOMES OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) STRATIFIED BY AGE IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) (EHA 2025 Abstract S114, FELIX subgroup)

29 PMC8214555 - Overcoming resistance to CAR T cell therapy (Review, June 2021, foundational concepts)

18 PMC5536094 - Chimeric Antigen Receptor T Cells for B-Cell Non-Hodgkin Lymphoma (Review, July 2017, foundational concepts)

177 OncLive - Investigators Focus on Reducing On-Target, Off-Tumor Toxicities With CAR T-Cell Therapy in Solid Tumors (Mar 2025)

25 ScienceDaily - Next-generation CAR T cell therapy works where other CAR T cell therapies have failed (May 2025, Penn's huCART19-IL18)

202 PMC10011202 - Cost-effectiveness of second-line axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma (Mar 2023)

287 JCO Oncology Practice - Long-Term Quality of Life, Cognitive Function, and Symptom Burden Among Chimeric Antigen Receptor T-Cell Recipients and Associated Cytokine Release Syndrome and Neurotoxicity (May 2025)

206 ASH Publications - Blood Advances - Socioeconomic, racial-ethnic, household, and infrastructural social vulnerabilities associate with decreased hematologic malignancy prognosis (Feb 2025)

207 PubMed - Socioeconomic, racial-ethnic, household, and infrastructural social vulnerabilities associate with decreased hematologic malignancy prognosis (Feb 2025)

189 ASCO Pubs - Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies (JCO, May 2025)

218 PMC4861363 - Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia (May 2016, foundational review)

219 ResearchGate - A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies (Feb 2025)

220 NCBI Bookshelf - Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version (Updated May 2025)

193 ResearchGate - Revving the CAR - Combination strategies to enhance CAR T cell effectiveness (Review, relevant concepts)

181 TCR AME Groups - Combination of CAR-T cell therapy and targeted drugs for B-cell lymphoma (Review, relevant concepts)

190 Allogene Press Release PDF - Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies (JCO, May 2025)

221 ResearchGate - The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (Oct 2023, relevant for access discussions)

166 Cell & Gene - Cell & Gene Therapies In 2025 Will Represent A Continuation Of FDA’s Developments From 2024 (May 2025, general regulatory update)

160 Targeted Oncology - FDA Grants Azer-Cel Fast Track Status in DLBCL (Mar 2025)

102 Autolus Press Release - Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel (May 2025)

103 GlobeNewswire - Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel (May 2025)

288 ResearchGate - Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (Mar 2025)

149 UHC Provider - Chimeric Antigen Receptor (CAR) T-Cell Therapy Policy (references PILOT PROs)

138 Gilead Press Release - Gilead and Kite Announce Presentation... (May 2025, ASCO/EHA KITE-363)

174 ASCO Pubs - KITE-363: A phase 1 study... (ASCO 2025 Abstract)

103 Autolus Press Release - Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA (Apr 2025)

104 Autolus Press Release - Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA (Apr 2025)

53 ResearchGate - Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma (2020, JULIET PROs)

138 Gilead Press Release - Gilead and Kite Announce Presentation... (May 2025, includes ASCO/EHA abstracts on Yescarta cost-effectiveness and QoL)

222 ASCO Pubs - Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for patients with advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 (ASCO 2025 Abstract, example of Q-TWiST, not directly CAR-T but relevant to PRO methodology)

223 ASCO Pubs - Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study (ASCO 2022 Poster, PILOT PROs)

135 OncLive - Brexu-Cel Demonstrates Efficacy, Safety in Older Patients With R/R Mantle Cell Lymphoma (Apr 2025, RWE)

139 ResearchGate - Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 (Mar 2025)

224 OncLive - Obe-cel Produces Durable Remissions in Adult R/R B-ALL (Feb 2025, FELIX data)

289 ASCO Pubs - Educational Book - Resistance to Immune Checkpoint Blockade (May 2022, general resistance concepts)

225 ASCO Pubs - Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium (JCO, Oct 2019, RWE)

124 Cancer Network - Axicabtagene Ciloleucel Shows OS Improvement in Large B-Cell Lymphoma (Dec 2023, ZUMA-7 subgroup)

226 OncLive - Liso-Cel and Pirtobrutinib Add Options in R/R CLL, Underscoring the Importance of Proper Treatment Selection (May 2024)

227 Dana-Farber Research News - Dana-Farber Research News 05-01-2025 (May 2025, various updates, some CAR-T related)

228 ASCO Pubs - Educational Book - Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults (May 2022)

229 OncLive - Obe-cel Elicits High MRD-Negative Response Rates in R/R B-ALL (Feb 2025, FELIX MRD data)

230 Bristol Myers Squibb Press Release - Bristol Myers Squibb to Present Data at ASCO® 2025... (May 2025, includes liso-cel abstracts)

231 ASCO Pubs - Prognostic value of circulating tumor DNA (ctDNA) detection by PhasED-Seq after axicabtagene ciloleucel (axi-cel) therapy in relapsed/refractory large B-cell lymphoma (LBCL) (ASCO 2025 Abstract, Yescarta)

232 Targeted Oncology - Assessing the Need for Extended Monitoring After Axi-Cel Infusion (May 2025)

199 Blood Cancers Today - Liso-Cel Versus Mosunetuzumab in Follicular Lymphoma: Cost, Clinical Outcomes, Time Toxicity (Feb 2025, TRANSCEND FL cost analysis)

167 Nasdaq - Gilead and Kite Announce Presentation... (May 2025, includes ASCO/EHA abstracts on Yescarta/Tecartus cost-effectiveness and QoL)

290 JCO - Real-World Outcomes With Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma (Oct 2022)

151 OncLive - FELIX Analysis Suggests Consolidative SCT After Obe-Cel Does Not Improve EFS/OS in R/R B-ALL (Apr 2025)

117 South Carolina Blues - Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies (Policy document, references ELIANA)

113 Novartis - The ELIANA Clinical Trial Fact Sheet (Jan 2018, pivotal ELIANA data)

118 Kymriah HCP - JULIET Study Design & Efficacy (DLBCL)

291 PMC11909426 - Real-world outcomes of patients with follicular lymphoma experiencing progression of disease within 24 months of frontline immunochemotherapy (May 2025, context for FL trials)

292 MDPI Cancers - Gemtuzumab Ozogamicin: The First Antibody–Drug Conjugate for Cancer Treatment and Its Impact on the Development of ADCs (May 2025, general ADC, not CAR-T)

122 PMC10646788 - Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (Nov 2023)

125 PMC10772511 - Three-year follow-up of axicabtagene ciloleucel in first-line high-risk large B-cell lymphoma: ZUMA-12 (Jan 2024)

128 Lymphoma Hub - ZUMA-5: 5-year follow-up analysis of axicabtagene ciloleucel in patients with R/R iNHL (Dec 2024)

145 Pharmacy Times - Lisocabtagene Maraleucel Expands the Therapeutic Landscape for Relapsed/Refractory Non-Hodgkin Lymphoma (May 2024)

293 ResearchGate - Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin–paclitaxel (RUBY trial) (Sep 2024, example of PRO reporting, not CAR-T)

147 Clinical Options - TRANSCEND CLL 004: Lisocabtagene Maraleucel in R/R CLL/SLL (ASCO 2023/Lancet 2023 data)

148 Blood Cancers Today - Phase II Data: Liso-Cel Overall, Complete Response Rates Favorable in Both MZL, Follicular Lymphoma (Feb 2025, TRANSCEND FL)

133 PubMed - Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study (May 2022)

136 Lymphoblastic Hub - ZUMA-3 trial: 3-year follow-up analysis (Apr 2025)

105 PMC10428320 - Obecabtagene autoleucel (obe-cel, AUTO1) for adult relapsed/refractory B-cell acute lymphoblastic leukemia (ALL): results from the pivotal FELIX study (Aug 2023, ASH abstract)

106 PubMed - Obecabtagene Autoleucel in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (Nov 2024, FELIX NEJM publication)

294 PMC12092082 - Patient-Reported Symptomatic Adverse Events in Adult Cancer Patients Receiving Immunotherapy and Molecular Targeted Therapy: A Scoping Review (May 2025)

295 JNCI Cancer Spectrum - Patient-Reported Symptomatic Adverse Events in Adult Cancer Patients Receiving Immunotherapy and Molecular Targeted Therapy: A Scoping Review (Feb 2025)

233 Kaiser Permanente - Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®) – Health Professional Information [NCI] (May 2025)

234 AMC Operations - AMC Bibliography (Mar 2025, lists ZUMA-12 abstract)

235 HemOnc.org Wiki - Chronic lymphocytic leukemia (general, not specific QoL for CAR-T)

236 ICML - 17-ICML Abstract Book (2023, example of conference abstracts, not specific to ASCO 2025)

219 ResearchGate - A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies (Feb 2025)

237 ASCO Pubs - Educational Book - Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults (May 2022)

238 Horizon Scan Geneesmiddelen - Horizonscan Geneesmiddelen (Dec 2022, Dutch HTA, not specific to ASCO 2025)

239 ResearchGate - Overcoming chimeric antigen receptor-T (CAR-T) resistance with checkpoint inhibitors: Existing methods, challenges, clinical success, and future prospects: A comprehensive review (Feb 2025)

213 ASCO Pubs - Educational Book - CAR T-Cell Therapy for Gastrointestinal Cancers (May 2024)

220 NCBI Bookshelf - Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version (May 2025)

210 Am J Med Case Rep - A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies (Feb 2025)

240 ResearchGate - Low Incidence of Invasive Fungal Disease Following CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Non-Hodgkin Lymphoma (Aug 2022)

241 ChemRxiv - Immuno-Oncology Co-occurrence (Preprint, not peer-reviewed, general IO)

242 ASCO Pubs - Educational Book - Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults (May 2022, general)

243 ResearchGate - BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy (Apr 2022, BCMA not CD19)

190 Allogene Press Release PDF - Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies (JCO, May 2025)

244 ASCO Pubs - Educational Book - CAR T-Cell Therapy: Toxicity and Management (May 2019, older but foundational)

189 ASCO Pubs - Prognostic value of circulating tumor DNA (ctDNA) detection by PhasED-Seq after axicabtagene ciloleucel (axi-cel) therapy in relapsed/refractory large B-cell lymphoma (LBCL) (ASCO 2025 Abstract)

245 AJMC - Most FDA and EMA Oncology Drug Approvals in Q1 2025 Were New Indications for Biologics and Biosimilars (May 2025, general approvals, not specific to CAR-T access)

246 JNCI Cancer Spectrum - Patient-Reported Symptomatic Adverse Events in Adult Cancer Patients Receiving Immunotherapy and Molecular Targeted Therapy: A Scoping Review (Feb 2025, general PROs)

247 Frontiers in Immunology - Real-world outcomes of CAR T-cell therapy in diffuse large B-cell lymphoma: a systematic review and meta-analysis (Aug 2024, general RWE)

134 JCO - Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study (May 2022)

139 ResearchGate - Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 (Mar 2025)

248 Finviz - Autolus Therapeutics Stock (Market data, not scientific)

53 ResearchGate - Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma (Feb 2020, JULIET PROs)

54 CADTH - CADTH Reimbursement Review: Tisagenlecleucel (Kymriah) for Follicular Lymphoma (Feb 2023)

65 PMC11665240 - Real-world versus clinical trial outcomes of axicabtagene ciloleucel in relapsed/refractory large B-cell lymphoma (May 2025)

296 Targeted Oncology - Phase 2 Study Supports Second-Line Axi-Cel in R/R LBCL (Jan 2024, ZUMA-12)

84 BioSpace - Bristol Myers Squibb to Present Data at ASCO 2025... (May 2025, includes liso-cel CRS/ICANS timing abstract)

297 Targeted Oncology - Liso-Cel Yields Meaningful Efficacy in R/R Mantle Cell Lymphoma (Feb 2024, TRANSCEND NHL 001 MCL cohort)

77 Targeted Oncology - Brexu-cel Shows Comparable Efficacy in Patients With B-ALL Aged 60-69 (Dec 2024, ZUMA-3 RWE)

135 OncLive - Brexu-cel Demonstrates Efficacy, Safety in Older Patients With R/R Mantle Cell Lymphoma (Apr 2025, RWE)

83 BioSpace - 5 CAR T-Cell Therapies with Autoimmune Readouts in 2025 (Feb 2025, includes obe-cel)

107 AJMC - MRD and Other Predictors From FELIX for Obe-Cel Success in R/R B-ALL (Dec 2024)

178 PMC12047531 - Resistance mechanisms to CAR T cell therapy in B cell malignancies (May 2025, review)

171 ResearchGate - Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia (Sep 2024, review)

172 ResearchGate - Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma (May 2025, general CAR-T challenges)

173 MDPI Cancers - Resistance to Immune Checkpoint Inhibitors in Cancer Therapy: Mechanisms and Therapeutic Strategies (May 2025, ICI resistance, some concepts overlap)

298 PMC11743624 - Recent advances in CAR T-cell therapy for solid tumors: challenges and future directions (May 2025, general CAR-T advancements)

211 ResearchGate - Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors (May 2025, general CAR-T advancements)

182 MDPI IJMS - Tumor Microenvironment and Immune Escape Mechanisms in Head and Neck Squamous Cell Carcinoma (May 2025, general TME)

299 PMC12009579 - Mosunetuzumab versus tisagenlecleucel for relapsed or refractory follicular lymphoma: a cost-effectiveness analysis (May 2025)

55 PMC12019763 - Real-World Evidence in European Medicines Agency Regulatory Decision-Making: A Review of Publicly Available Information (May 2025, includes CAR-T examples)

66 ASH Publications - Blood - Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma: ZUMA-12 (May 2025)

198 ResearchGate - Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial (May 2025)

300 PMC12025827 - Indirect treatment comparison of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma (May 2025)

301 JMCP - Cost-Effectiveness of Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma in the United States (Mar 2025)

203 PMC11871159 - Real-World Treatment Patterns and Health Care Resource Utilization in Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With CAR T Versus Non–CAR T Standard-of-Care Therapies (Mar 2025)

200 ResearchGate - Cost-effectiveness studies of brexu-cel for Relapsed/Refractory B-Cell acute lymphoblastic leukemia and Mantle Cell Lymphoma: a systematic review (Dec 2024)

204 Nasdaq - Autolus Therapeutics to Present Data at 2025 Tandem Meetings on AUCATZYL® and its Economic Impact (Jan 2025)

302 GovInfo - FY 2026 IPPS/LTCH PPS Proposed Rule (Apr 2025, general healthcare policy, not specific to CAR-T economics)

This is a massive undertaking. I will focus on synthesizing the information logically and ensuring all key aspects from the outline are covered with appropriate depth and citation. The word count will be a challenge to manage while being comprehensive. I will prioritize clarity and scientific accuracy.# Chimeric Antigen Receptor T-Cell Therapy Targeting CD19 (CART-19): A Comprehensive Report

1. Introduction to CART-19 Therapy

Defining CART-19: A Revolutionary Cellular Immunotherapy

Chimeric Antigen Receptor T-cell (CART) therapy targeting the CD19 protein, commonly referred to as CART-19, represents a groundbreaking advancement in cellular immunotherapy. This therapeutic modality involves the collection of a patient's own T-lymphocytes (autologous T-cells), which are then genetically engineered ex vivo to express a synthetic receptor—the CAR—that specifically recognizes the CD19 antigen present on the surface of targeted cells.[1] Following genetic modification and expansion to achieve a therapeutic dose, these engineered CART-19 cells are infused back into the patient, where they can identify and eliminate CD19-expressing cancer cells.[2] This personalized approach has demonstrated unprecedented efficacy, particularly in the treatment of relapsed or refractory (r/r) B-cell hematological malignancies, offering new hope and potentially curative outcomes for patients with otherwise limited options.[1] The remarkable clinical success has led to the approval of several CART-19 products by major regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).[3]

The emergence of CART-19 therapy signifies a fundamental paradigm shift in oncology, moving beyond conventional "drug-centric" treatments towards "living drug" approaches.[1] Unlike traditional pharmaceuticals, CART-19 cells are dynamic biological entities capable of proliferation, persistence, and sustained effector function within the patient.[3] This "living" characteristic results in unique pharmacokinetic and pharmacodynamic profiles and is associated with distinct toxicity patterns, such as Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), which arise from the potent activation of the engineered T-cells and the subsequent release of inflammatory cytokines.[14] Furthermore, the potential for these cells to establish long-term immunological memory and provide ongoing surveillance against cancer recurrence underscores their novelty.[13] Consequently, the entire lifecycle of CART-19 therapy—from patient selection and cell collection through manufacturing, administration, and long-term monitoring—requires specialized expertise and infrastructure.

The Significance of the CD19 Target in B-Cell Malignancies

The CD19 protein is a B-lymphocyte-specific transmembrane glycoprotein belonging to the immunoglobulin superfamily. It is expressed on the surface of B-cells throughout most stages of their differentiation, from early pro-B cells to mature B-cells, but is notably absent on hematopoietic stem cells, plasma cells, and most other non-hematopoietic tissues.[1] Critically for therapeutic targeting, CD19 is also expressed on the vast majority of malignant B-cells, including those found in B-cell acute lymphoblastic leukemia (B-ALL), various forms of non-Hodgkin lymphoma (NHL) such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL).[1]

This expression profile—consistently high on most normal and malignant B-cells but restricted outside the B-cell lineage—makes CD19 an exceptionally attractive target for immunotherapy. Targeting CD19 allows for potent and selective elimination of malignant B-cells. While this approach also leads to the depletion of the normal B-cell population (B-cell aplasia), an on-target, off-tumor effect, the sparing of other essential cell types minimizes broader systemic toxicities often associated with conventional chemotherapy.[1] The profound clinical responses achieved with multiple CART-19 therapies have unequivocally validated CD19 as a pivotal therapeutic target in B-cell cancers.[1] However, the inevitable consequence of targeting CD19 is B-cell aplasia, which leads to hypogammaglobulinemia and an increased risk of infections. This necessitates careful long-term monitoring and often prophylactic measures, such as intravenous immunoglobulin (IVIG) replacement, highlighting a central tenet of CAR T-cell therapy: the specificity of the target antigen dictates both the therapeutic efficacy and a predictable spectrum of manageable adverse events.[16]

2. Mechanism of Action of CART-19 Cells

Engineering T-Cells: Structure of Chimeric Antigen Receptors (CARs)

Chimeric Antigen Receptors are synthetic proteins that are not naturally found in T-cells; they are introduced into T-cells using genetic engineering techniques, typically viral transduction.[1] The fundamental design of a CAR combines the antigen-recognition capability of an antibody with the T-cell's own signaling apparatus, enabling the CAR T-cell to identify and respond to target cells in a direct, MHC-unrestricted manner.[1] This MHC independence is a significant advantage, as tumors often downregulate MHC expression to evade conventional T-cell immunity.[22]

The structure of a CAR is modular, typically consisting of:

• Extracellular Antigen-Binding Domain: For CART-19 therapies, this is usually a single-chain variable fragment (scFv) derived from a monoclonal antibody that specifically binds to the CD19 protein on B-cells.[1] The affinity and specificity of this scFv are critical determinants of the CAR T-cell's targeting ability.
• Hinge or Spacer Region: This flexible domain connects the scFv to the transmembrane domain. Its length and composition can affect CAR expression, accessibility of the scFv to the target antigen, and the formation of the immunological synapse between the CAR T-cell and the target cell.[22]
• Transmembrane Domain: This portion anchors the CAR within the T-cell membrane and transmits signals from the extracellular binding event to the intracellular signaling components.[22] Commonly used transmembrane domains are derived from CD8α or CD28.
• Intracellular Signaling Domain(s): These are essential for T-cell activation upon antigen engagement.
• Primary Activation Domain (CD3-zeta): The CD3ζ chain, derived from the T-cell receptor (TCR)/CD3 complex, contains immunoreceptor tyrosine-based activation motifs (ITAMs). Phosphorylation of these ITAMs upon CAR ligation initiates the T-cell activation cascade.[1] First-generation CARs, containing only the CD3ζ domain, showed limited clinical success due to poor T-cell proliferation, persistence, and cytokine production in vivo.[11]
• Costimulatory Domain(s): To enhance T-cell function, second-generation CARs (which include all currently FDA/EMA-approved CART-19 products) incorporate one intracellular costimulatory domain in addition to CD3ζ.[1] The most common costimulatory domains are CD28 and 4-1BB (CD137). These domains provide crucial secondary signals that significantly augment T-cell proliferation, survival, cytokine secretion, and cytotoxic activity, leading to more robust and sustained anti-tumor responses.[22] The choice of costimulatory domain profoundly influences the biological characteristics of the CAR T-cells. CD28 costimulation typically leads to rapid and vigorous T-cell

Works cited

1. Next Generation Chimeric Antigen Receptor T Cell Therapy: Going off the Shelf - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5699508/
2. CAR T-Cell Therapy - Dana-Farber Cancer Institute, accessed May 24, 2025, https://www.dana-farber.org/cancer-care/treatment/cellular-therapies/car-t-cell-therapy
3. CAR T cell - Wikipedia, accessed May 24, 2025, https://en.wikipedia.org/wiki/CAR_T_cell
4. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS | Blood | American Society of Hematology, accessed May 24, 2025, https://ashpublications.org/blood/article/143/3/258/498424/CD19-occupancy-with-tafasitamab-increases
5. From bench to bedside: the history and progress of CAR T cell therapy - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10225594/
6. The Process of CAR-T Cell Therapy - Novartis, accessed May 24, 2025, https://www.novartis.com/research-and-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-healthcare-professionals/process-car-t-cell-therapy
7. CAR-T manufacturing: process and supply chain strategies | Single Use Support, accessed May 24, 2025, https://www.susupport.com/knowledge/biopharmaceutical-products/cell-gene-therapy/car-t-manufacturing-process-supply-chain
8. Overview of approved CAR-T products and utility in clinical practice - PMC, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11514108/
9. Approved CAR-T therapies have reproducible efficacy and safety in clinical practice, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11305028/
10. CAR T Cell Therapy: A Versatile Living Drug - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10094630/
11. The Long Road to the First FDA Approved Gene Therapy: Chimeric Antigen Receptor T Cells Targeting CD19, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7036015/
12. A brief history of CAR-T cells: from laboratory to the bedside - Via Medica Journals, accessed May 24, 2025, https://journals.viamedica.pl/acta_haematologica_polonica/article/download/75176/54981
13. What is the mechanism of Tisagenlecleucel? - Patsnap Synapse, accessed May 24, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-tisagenlecleucel
14. CAR T-cell Therapy and Its Side Effects | American Cancer Society, accessed May 24, 2025, https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/car-t-cell1.html
15. Cytokine release syndrome - The Journal for ImmunoTherapy of Cancer, accessed May 24, 2025, https://jitc.bmj.com/content/6/1/56
16. Toxicities of chimeric antigen receptor T cells: recognition and management | Blood | American Society of Hematology, accessed May 24, 2025, https://ashpublications.org/blood/article/127/26/3321/35340/Toxicities-of-chimeric-antigen-receptor-T-cells
17. Axicabtagene ciloleucel: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed May 24, 2025, https://go.drugbank.com/drugs/DB13915
18. CD19-Targeted CAR T Cells as Novel Cancer Immunotherapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5536094/
19. Management of Hypogammaglobulinaemia and B-Cell Aplasia - The EBMT/EHA CAR-T Cell Handbook - NCBI Bookshelf, accessed May 24, 2025, https://www.ncbi.nlm.nih.gov/books/NBK584138/
20. Hypogammaglobulinemia after Chimeric Antigen Receptor (CAR) T-cell therapy: characteristics, management, and future directions, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8837681/
21. Overview of infectious complications among CAR T- cell therapy recipients - Frontiers, accessed May 24, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1398078/full
22. Engineering and Design of Chimeric Antigen Receptors - PMC, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6330382/
23. Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond - PMC, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11880241/
24. Enhanced CAR T cell therapy offers new strategy for lymphoma | Penn Today, accessed May 24, 2025, https://penntoday.upenn.edu/news/penn-medicine-enhanced-car-t-cell-therapy-offers-new-strategy-lymphoma
25. Enhanced CAR T cell therapy offers new strategy for lymphoma | ScienceDaily, accessed May 24, 2025, https://www.sciencedaily.com/releases/2025/05/250507200803.htm
26. Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases - MDPI, accessed May 24, 2025, https://www.mdpi.com/1424-8247/18/2/156
27. KYMRIAH® (tisagenlecleucel) | Official Patient Website, accessed May 24, 2025, https://us.kymriah.com/
28. YESCARTA® (axicabtagene ciloleucel) Treatment Process | Patient & Caregiver Site, accessed May 24, 2025, https://www.yescarta.com/receiving-yescarta
29. Mechanisms of resistance to CAR T cell therapy - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8214555/
30. How is Kymriah administered? - Drugs.com, accessed May 24, 2025, https://www.drugs.com/medical-answers/kymriah-administered-3331549/
31. Results with Breyanzi® (lisocabtagene maraleucel), accessed May 24, 2025, https://www.breyanzi.com/how-breyanzi-helps/results-with-breyanzi
32. Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia - PMC, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10664098/
33. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10770848/
34. Lymphodepletion optimization for CAR T-cell therapy - Multiple Myeloma Hub, accessed May 24, 2025, https://multiplemyelomahub.com/medical-information/lymphodepletion-optimization-for-car-t-cell-therapy
35. Manufacturing & Process | YESCARTA® (axicabtagene ciloleucel), accessed May 24, 2025, https://www.yescartahcp.com/large-b-cell-lymphoma/manufacturing-and-process
36. Tecartus | European Medicines Agency (EMA), accessed May 24, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus
37. CAR T Safety and Management, accessed May 24, 2025, https://www.carthope.com/safety
38. Outpatient CAR-T Therapy Revolutionizing Cancer Treatment - U.S. Pharmacist, accessed May 24, 2025, https://www.uspharmacist.com/article/outpatient-cart-therapy-revolutionizing-cancer-treatment
39. U.S. FDA Approves Kite's Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma - Gilead Sciences, accessed May 24, 2025, https://www.gilead.com/news/news-details/2020/us-fda-approves-kites-tecartus-the-first-and-only-car-t-treatment-for-relapsed-or-refractory-mantle-cell-lymphoma
40. Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access | JCO Oncology Practice - ASCO Publications, accessed May 24, 2025, https://ascopubs.org/doi/10.1200/OP.22.00315
41. Risk Evaluation and Mitigation Strategies | REMS - FDA, accessed May 24, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems
42. CARVYKTI REMS, accessed May 24, 2025, https://www.carvyktirems.com/
43. YESCARTA® (axicabtagene ciloleucel) Safety Information | HCP, accessed May 24, 2025, https://www.yescartahcp.com/2l-large-b-cell-lymphoma/safety
44. KYMRIAH | FDA, accessed May 24, 2025, https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah
45. Adverse Events & Safety | KYMRIAH® (tisagenlecleucel) | HCP, accessed May 24, 2025, https://www.kymriah-hcp.com/acute-lymphoblastic-leukemia-children/safety-profile
46. Safety Profile - KYMRIAH-HCP.com, accessed May 24, 2025, https://www.kymriah-hcp.com/diffuse-large-b-cell-lymphoma-adults/safety-profile
47. Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma, accessed May 24, 2025, https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Receives-Approval-from-the-European-Commission-to-Expand-Use-of-CAR-T-Cell-Therapy-Breyanzi-for-Relapsed-or-Refractory-Follicular-Lymphoma/default.aspx
48. Receiving CAR T-cells gets faster, but not for all in need | Blood Advances, accessed May 24, 2025, https://ashpublications.org/bloodadvances/article/9/2/436/535280/Receiving-CAR-T-cells-gets-faster-but-not-for-all
49. Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network | Blood Advances | American Society of Hematology, accessed May 24, 2025, https://ashpublications.org/bloodadvances/article/9/2/429/518217/Access-barriers-to-anti-CD19-CART-therapy-for-NHL
50. KYMRIAH (Tisagenlecleucel) - Boston Children's Hospital, accessed May 24, 2025, https://www.childrenshospital.org/treatments/kymriah-tisagenlecleucel
51. Search Orphan Drug Designations and Approvals - FDA, accessed May 24, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=463114
52. Kymriah | European Medicines Agency (EMA), accessed May 24, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah
53. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma | Request PDF - ResearchGate, accessed May 24, 2025, https://www.researchgate.net/publication/339372638_Patient-reported_long-term_quality_of_life_after_tisagenlecleucel_in_relapsedrefractory_diffuse_large_B-cell_lymphoma?_tp=eyJjb250ZXh0Ijp7InBhZ2UiOiJzY2llbnRpZmljQ29udHJpYnV0aW9ucyIsInByZXZpb3VzUGFnZSI6bnVsbCwic3ViUGFnZSI6bnVsbH19
54. View of Tisagenlecleucel (Kymriah) | Canadian Journal of Health Technologies, accessed May 24, 2025, https://canjhealthtechnol.ca/index.php/cjht/article/view/PG0306r/1649
55. The role and value of real-world evidence in health technology decision-making in France, Germany, Italy, Spain, and the UK: insights on external control arms - PMC, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12019763/
56. Tisagenlecleucel: Uses, Dosage, Side Effects & Warnings - Drugs.com, accessed May 24, 2025, https://www.drugs.com/tisagenlecleucel.html
57. Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10294746/
58. Tisagenlecleucel - Wikipedia, accessed May 24, 2025, https://en.wikipedia.org/wiki/Tisagenlecleucel
59. EMA Recommends First CART-T Cell Therapies - BioPharm International, accessed May 24, 2025, https://www.biopharminternational.com/view/ema-recommends-first-cart-t-cell-therapies-0
60. Kymriah, INN-tisagenlecleucel - European Medicines Agency, accessed May 24, 2025, https://www.ema.europa.eu/en/documents/product-information/kymriah-epar-product-information_en.pdf
61. Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan - Gilead Sciences, accessed May 24, 2025, https://www.gilead.com/news/news-details/2021/daiichi-sankyo-authorizes-the-first-yescarta-axicabtagene-ciloleucel-car-t-cell-therapy-treatment-site-in-japan
62. Axicabtagene Ciloleucel (YESCARTA®) - NIH Office of Technology Transfer, accessed May 24, 2025, https://www.techtransfer.nih.gov/sites/default/files/documents/pdfs/Impact%20Study/Yescarta%20Case%20Study.pdf
63. Kite Seeks EU Approval for CAR T-Cell Therapy in 3 Lymphoma Subtypes, accessed May 24, 2025, https://lymphomanewstoday.com/2017/08/03/kite-seeks-e-u-approval-car-t-cell-therapy-3-lymphoma-subtypes/
64. FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma, accessed May 24, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axicabtagene-ciloleucel-second-line-treatment-large-b-cell-lymphoma
65. Benefit of axicabtagene ciloleucel vs chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11665240/
66. Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study | Blood - ASH Publications, accessed May 24, 2025, https://ashpublications.org/blood/article/145/20/2303/535581/Three-year-follow-up-analysis-of-first-line
67. Axicabtagene Ciloleucel - PubChem, accessed May 24, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Axicabtagene-Ciloleucel
68. Real-world Evidence of Axicabtagene Ciloleucel for the Treatment of Large B-Cell Lymphoma in the United States - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9427701/
69. Yescarta First CAR T-Cell Therapy Approved for Follicular Lymphoma, accessed May 24, 2025, https://jhoponline.com/issue-archive/2021-issues/april-2021-vol-10-no-2/yescarta-first-car-t-cell-therapy-approved-for-follicular-lymphoma
70. FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma, accessed May 24, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-axicabtagene-ciloleucel-relapsed-or-refractory-follicular-lymphoma
71. Yescarta, INN-axicabtagene ciloleucel - European Medicines Agency, accessed May 24, 2025, https://www.ema.europa.eu/en/documents/product-information/yescarta-epar-product-information_en.pdf
72. Brexucabtagene autoleucel - Kite Pharma - AdisInsight - Springer, accessed May 24, 2025, https://adisinsight.springer.com/drugs/800058300
73. TECARTUS® (brexucabtagene autoleucel) Patient & Caregiver Site | CAR T-Cell Therapy for Mantle Cell Lymphoma, accessed May 24, 2025, https://www.tecartus.com/
74. The Power of Brexucabtagene Autoleucel in Mantle Cell Lymphoma - OncologyTube, accessed May 24, 2025, https://oncologytube.com/brexucabtagene-autoleucel/
75. Tecartus (brexucabtagene autoleucel) for the Treatment of Mantle Cell Lymphoma (MCL), accessed May 24, 2025, https://www.clinicaltrialsarena.com/projects/tecartus-brexucabtagene-autoleucel/
76. FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia, accessed May 24, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic
77. Brexu-cel Shows Comparable Efficacy in Patients With B-ALL Aged 60-69, accessed May 24, 2025, https://www.targetedonc.com/view/brexu-cel-shows-comparable-efficacy-in-patients-with-b-all-aged-60-69
78. Clinical Policy: Brexucabtagene Autoleucel (Tecartus) - PA Health & Wellness, accessed May 24, 2025, https://www.pahealthwellness.com/content/dam/centene/Pennsylvania/policies/clinical-policies/Brexucabtagene-autoleucel-Tecartus-v1-2024.pdf
79. Brexucabtagene autoleucel - Wikipedia, accessed May 24, 2025, https://en.wikipedia.org/wiki/Brexucabtagene_autoleucel
80. Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma, accessed May 24, 2025, https://investors.bms.com/iframes/press-releases/press-release-details/2025/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-for-Breyanzi-lisocabtagene-maraleucel-in-Adult-Patients-with-Relapsed-or-Refractory-Marginal-Zone-Lymphoma/default.aspx
81. Lisocabtagene maraleucel - Wikipedia, accessed May 24, 2025, https://en.wikipedia.org/wiki/Lisocabtagene_maraleucel
82. FDA Approves Breyanzi for Advanced Large B-Cell Lymphoma, accessed May 24, 2025, https://oncpracticemanagement.com/issues/2021/march-2021-vol-11-no-3/fda-approves-breyanzi-for-advanced-large-b-cell-lymphoma
83. 5 CAR T Cell Therapies With Autoimmune Readouts in 2025 - BioSpace, accessed May 24, 2025, https://www.biospace.com/drug-development/5-car-t-cell-therapies-with-autoimmune-readouts-in-2025
84. Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline - BioSpace, accessed May 24, 2025, https://www.biospace.com/press-releases/bristol-myers-squibb-to-present-data-at-asco-2025-highlighting-differentiated-research-platform-of-oncology-treatments-and-innovative-research-pipeline
85. In Brief: Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma (online only), accessed May 24, 2025, https://secure.medicalletter.org/TML-article-1679f
86. Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL - Oncology Nursing News, accessed May 24, 2025, https://www.oncnursingnews.com/view/liso-cel-shows-comparable-real-world-outcomes-in-relapsed-refractory-lbcl
87. CHMP Recommends Approval of Liso-Cel for Follicular Lymphoma | Blood Cancers Today, accessed May 24, 2025, https://www.bloodcancerstoday.com/post/chmp-recommends-approval-of-liso-cel-for-follicular-lymphoma
88. Liso-Cel Receives European Approval in Relapsed/Refractory Follicular Lymphoma, accessed May 24, 2025, https://www.onclive.com/view/liso-cel-receives-european-approval-in-relapsed-refractory-follicular-lymphoma
89. FDA Approves Liso-Cel in Relapsed or Refractory CLL/SLL - Targeted Oncology, accessed May 24, 2025, https://www.targetedonc.com/view/fda-approves-liso-cel-in-relapsed-or-refractory-cll-sll
90. CAR T Approval: What It Means for Patients With CLL, accessed May 24, 2025, https://www.patientpower.info/video/chronic-lymphocytic-leukemia/car-t-approval-what-it-means-for-patients-with-cll
91. U.S. FDA Approves Bristol Myers Squibb's Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), accessed May 24, 2025, https://news.bms.com/news/details/2024/U.S.-FDA-Approves-Bristol-Myers-Squibbs-Breyanzi--as-the-First-and-Only-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukemia-CLL-or-Small-Lymphocytic-Lymphoma-SLL/default.aspx
92. Liso-Cel Prolongs Responses, PFS, and OS in Pretreated, High-Risk, R/R CLL - OncLive, accessed May 24, 2025, https://www.onclive.com/view/liso-cel-prolongs-responses-pfs-and-os-in-pretreated-high-risk-r-r-cll
93. EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel, accessed May 24, 2025, https://www.esmo.org/oncology-news/ema-recommends-extension-of-therapeutic-indications-for-lisocabtagene-maraleucel2
94. Regenerative medicine advanced therapy - Wikipedia, accessed May 24, 2025, https://en.wikipedia.org/wiki/Regenerative_medicine_advanced_therapy
95. CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI, accessed May 24, 2025, https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
96. Aucatzyl (obecabtagene autoleucel) FDA Approval History - Drugs.com, accessed May 24, 2025, https://www.drugs.com/history/aucatzyl.html
97. FDA Approves Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia - OncLive, accessed May 24, 2025, https://www.onclive.com/view/fda-approves-obecabtagene-autoleucel-for-r-r-b-cell-precursor-acute-lymphoblastic-leukemia
98. Aucatzyl | European Medicines Agency (EMA), accessed May 24, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/aucatzyl
99. Obe-Cel Receives Positive CHMP Opinion for R/R B-Cell ALL - CancerNetwork, accessed May 24, 2025, https://www.cancernetwork.com/view/obe-cel-receives-positive-chmp-opinion-for-r-r-b-cell-all
100. Autolus Therapeutics Provides Business Updates and 2025 Overview, accessed May 24, 2025, https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-provides-business-updates-and-2025-overview
101. Developing Next Generation Programmed T Cell Therapies - Autolus, accessed May 24, 2025, https://www.autolus.com/media/5gwhqla5/2505-q2-corporate-presentation.pdf
102. Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL), accessed May 24, 2025, https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-announces-positive-chmp-opinion
103. Autolus Therapeutics Announces Positive CHMP Opinion for - GlobeNewswire, accessed May 24, 2025, https://www.globenewswire.com/news-release/2025/05/23/3087452/0/en/Autolus-Therapeutics-Announces-Positive-CHMP-Opinion-for-Obecabtagene-Autoleucel-for-Adult-Patients-age-26-and-older-with-Relapsed-or-Refractory-B-Cell-Precursor-Acute-Lymphoblasti.html
104. Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1), accessed May 24, 2025, https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-announces-license-aucatzylr-obecabtagene
105. S262: SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL), A FAST-OFF RATE CD19 CAR IN RELAPSED/REFRACTORY ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA:TOP LINE RESULTS OF THE PIVOTAL FELIX STUDY - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10428320/
106. Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia - PubMed, accessed May 24, 2025, https://pubmed.ncbi.nlm.nih.gov/39602653/
107. MRD and Other Predictors From FELIX for Obe-Cel Success in R/R B-ALL, accessed May 24, 2025, https://www.ajmc.com/view/mrd-and-other-predictors-from-felix-for-obe-cel-success-in-r-r-b-all
108. CAR-T Updates 2025: Latest FDA-Approved Treatments and Advancements, accessed May 24, 2025, https://israelihospitals.org.il/car-t-updates-2025-latest-fda-approved-treatments-and-advancements.html
109. New treatment for adults with acute lymphoblastic leukaemia - European Medicines Agency, accessed May 24, 2025, https://www.ema.europa.eu/en/news/new-treatment-adults-acute-lymphoblastic-leukaemia
110. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 May 2025, accessed May 24, 2025, https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-may-2025
111. Definition of lisocabtagene maraleucel - NCI Dictionary of Cancer Terms, accessed May 24, 2025, https://www.cancer.gov/publications/dictionaries/cancer-terms/def/lisocabtagene-maraleucel
112. Chimeric Antigen Receptor Therapy for Hematologic Malignancies, accessed May 24, 2025, https://www.southcarolinablues.com/web/public/brands/medicalpolicyih/external-policies/chimeric-antigen-receptor-therapy-for-hematologic-malignancies
113. The ELIANA Clinical Trial Fact Sheet - Novartis, accessed May 24, 2025, https://novartis.gcs-web.com/static-files/110bee95-5916-483f-a0c9-20128105005f
114. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial - PubMed, accessed May 24, 2025, https://pubmed.ncbi.nlm.nih.gov/31606419/
115. Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry | Journal for ImmunoTherapy of Cancer, accessed May 24, 2025, https://jitc.bmj.com/content/13/2/e009890
116. Prediction of Poor Outcome after Tisagenlecleucel in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Using Artificial Intelligence Analysis of Pre-Infusion PET/CT | Blood | American Society of Hematology, accessed May 24, 2025, https://ashpublications.org/blood/article/140/Supplement%201/1919/492740/Prediction-of-Poor-Outcome-after-Tisagenlecleucel
117. Chimeric Antigen Receptor Therapy for Hematologic Malignancies, accessed May 24, 2025, https://www.southcarolinablues.com/web/public/brands/medicalpolicyih/external-policies/chimeric-antigen-receptor-therapy-for-hematologic-malignancies/
118. Efficacy Data | KYMRIAH® (tisagenlecleucel) for DLBCL | HCP, accessed May 24, 2025, https://www.kymriah-hcp.com/diffuse-large-b-cell-lymphoma-adults/efficacy
119. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update | Blood | American Society of Hematology, accessed May 24, 2025, https://ashpublications.org/blood/article/143/17/1713/507096/Durable-response-after-tisagenlecleucel-in-adults
120. FL Efficacy Data | KYMRIAH® (tisagenlecleucel) | HCP, accessed May 24, 2025, https://www.kymriah-hcp.com/follicular-lymphoma-adults/efficacy
121. Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial. - ASCO, accessed May 24, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT332979
122. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10646788/
123. Outcomes of subsequent therapies after 2L axi-cel or SOC in R/R LBCL: ZUMA-7 study, accessed May 24, 2025, https://lymphomahub.com/medical-information/outcomes-of-subsequent-therapies-after-2l-axi-cel-or-soc-in-rr-lbcl-zuma-7-study
124. Axicabtagene Ciloleucel Shows OS Improvement in Large B-Cell Lymphoma, accessed May 24, 2025, https://www.cancernetwork.com/view/axicabtagene-ciloleucel-shows-os-improvement-in-large-b-cell-lymphoma
125. Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7), accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10772511/
126. Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7, accessed May 24, 2025, https://www.asco.org/posters/POSTER362126
127. CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9761215/
128. ZUMA-5: 5-year follow-up analysis of axicabtagene ciloleucel in patients with R/R iNHL, accessed May 24, 2025, https://lymphomahub.com/medical-information/zuma-5-5-year-follow-up-analysis-of-axicabtagene-ciloleucel-in-patients-with-rr-inhl
129. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5) - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10934297/
130. Tecartus (brexucabtagene autoleucel) dosing, indications, interactions, adverse effects, and more - Medscape, accessed May 24, 2025, https://reference.medscape.com/drug/tecartus-brexucabtagene-autoleucel-4000069
131. ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups, accessed May 24, 2025, https://www.onclive.com/view/zuma-2-data-support-earlier-line-role-for-brexu-cel-in-high-risk-r-r-mcl-subgroups
132. Brexu-Cel Yields High Response Rates in Relapsed/Refractory, BTK-Naive MCL - Oncology Nursing News, accessed May 24, 2025, https://www.oncnursingnews.com/view/brexu-cel-yields-high-response-rates-in-relapsed-refractory-btk-naive-mcl
133. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study - PubMed, accessed May 24, 2025, https://pubmed.ncbi.nlm.nih.gov/35658525/
134. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study | Journal of Clinical Oncology - ASCO Publications, accessed May 24, 2025, https://ascopubs.org/doi/10.1200/JCO.21.02370
135. Brexu-Cel Demonstrates Efficacy, Safety in Older Patients with R/R Mantle Cell Lymphoma, accessed May 24, 2025, https://www.onclive.com/view/brexu-cel-demonstrates-efficacy-safety-in-older-patients-with-r-r-mantle-cell-lymphoma
136. ZUMA-3 trial: 3-year follow-up analysis - ALL Hub, accessed May 24, 2025, https://lymphoblastic-hub.com/medical-information/zuma-3-trial-3-year-follow-up-analysis
137. Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). - ASCO, accessed May 24, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT334183
138. Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple Negative Breast Cancer Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA, accessed May 24, 2025, https://www.gilead.com/news/news-details/2025/gilead-and-kite-announce-presentation-of-transformative-data-in-1l-metastatic-triple-negative-breast-cancer-updated-results-in-multiple-myeloma-and-early-data-from-novel-investigational-car-
139. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 - ResearchGate, accessed May 24, 2025, https://www.researchgate.net/publication/389991292_Three-year_analysis_of_adult_patients_with_relapsed_or_refractory_B-cell_acute_lymphoblastic_leukemia_treated_with_brexucabtagene_autoleucel_in_ZUMA-3
140. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL - PubMed, accessed May 24, 2025, https://pubmed.ncbi.nlm.nih.gov/39418622/
141. Outcomes With Brexucabtagene Autoleucel as Standard Therapy for Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia - The ASCO Post, accessed May 24, 2025, https://ascopost.com/news/october-2024/outcomes-with-brexucabtagene-autoleucel-as-standard-therapy-for-adults-with-relapsedrefractory-b-cell-acute-lymphoblastic-leukemia/
142. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001 | Blood | American Society of Hematology, accessed May 24, 2025, https://ashpublications.org/blood/article/143/5/404/498484/Two-year-follow-up-of-lisocabtagene-maraleucel-in
143. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001 - PubMed, accessed May 24, 2025, https://pubmed.ncbi.nlm.nih.gov/37890149/
144. Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11993828/
145. Lisocabtagene Maraleucel Expands the Therapeutic Landscape for Relapsed/Refractory Non-Hodgkin Lymphoma - Pharmacy Times, accessed May 24, 2025, https://www.pharmacytimes.com/view/lisocabtagene-maraleucel-expands-the-therapeutic-landscape-for-relapsed-refractory-non-hodgkin-lymphoma
146. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9713278/
147. TRANSCEND CLL 004: Phase I/II Trial of Lisocabtagene Maraleucel for Relapsed/Refractory CLL/SLL - CCO, accessed May 24, 2025, https://clinicaloptions.com/activities/download/15046/slug/transcend-cll-004-1/25046
148. Phase II Data: Liso-Cel Overall, Complete Response Rates Favorable in Both MZL, Follicular Lymphoma | Blood Cancers Today, accessed May 24, 2025, https://www.bloodcancerstoday.com/post/phase-ii-data-liso-cel-overall-complete-response-rates-favorable-in-both-mzl-follicular-lymphoma
149. Chimeric Antigen Receptor T-Cell (CAR T) Therapy - UHCprovider.com, accessed May 24, 2025, https://www.uhcprovider.com/content/dam/provider/docs/public/policies/clinical-guidelines/chimeric-antigen-receptor-tcell-therapy.pdf
150. EFFICACY AND SAFETY OUTCOMES OF OBECABTAGENE AUTOLEUCEL (OBE-CEL)... by Bijal D. Shah - EHA Library, accessed May 24, 2025, https://library.ehaweb.org/eha/2025/eha2025-congress/4159191/bijal.d.shah.efficacy.and.safety.outcomes.of.obecabtagene.autoleucel.28obe-cel29.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31558%2Amarker%3D5843%2Afeatured%3D19595
151. FELIX Analysis Suggests Consolidative SCT After Obe-Cel Does Not Improve EFS/OS in R/R B-ALL - OncLive, accessed May 24, 2025, https://www.onclive.com/view/felix-analysis-suggests-consolidative-sct-after-obe-cel-does-not-improve-efs-os-in-r-r-b-all
152. CAR-T cell therapy recipient in the ICU - EMCrit Project, accessed May 24, 2025, https://emcrit.org/ibcc/cart/
153. Dr Lee on the Real-World Safety Profile of Axi-Cel in R/R LBCL - OncLive, accessed May 24, 2025, https://www.onclive.com/view/dr-lee-on-the-real-world-safety-profile-of-axi-cel-in-r-r-lbcl
154. Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11532742/
155. Anakinra Ineffective in Preventing CRS/ICANS After Liso-cel in LBCL - CancerNetwork, accessed May 24, 2025, https://www.cancernetwork.com/view/anakinra-ineffective-in-preventing-crs-icans-after-liso-cel-in-lbcl
156. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9445841/
157. pmc.ncbi.nlm.nih.gov, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9445841/#:~:text=Clinically%2C%20ICANS%20can%20present%20from,14%2C%2020%2C%2027)..&sa=D&source=editors&ust=1748082335064203&usg=AOvVaw3txm0HB5PNtiVBomNpGVos)
158. Full article: Unmet needs and lived experience of patients receiving CAR T-cell therapy, accessed May 24, 2025, https://www.tandfonline.com/doi/full/10.1080/10428194.2025.2455488?af=R
159. Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma - Frontiers, accessed May 24, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1404351/full
160. FDA Grants Azer-Cel Fast Track Status in DLBCL - Targeted Oncology, accessed May 24, 2025, https://www.targetedonc.com/view/fda-grants-azer-cel-fast-track-status-in-dlbcl
161. Case Report: Invasive fungal infection after anti-CD19 CAR-T cell therapy. Implication for antifungal prophylaxis - Frontiers, accessed May 24, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1272798/full
162. Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies - NCI, accessed May 24, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-02972
163. New Perspectives on the Risk of Secondary Cancers After CAR T-cell Therapy, accessed May 24, 2025, https://www.aacr.org/blog/2024/09/16/new-perspectives-on-the-risk-of-secondary-cancers-after-car-t-cell-therapy/
164. Safe CAR-T: shedding light on CAR-related T-cell malignancies | EMBO Molecular Medicine, accessed May 24, 2025, https://www.embopress.org/doi/10.1038/s44321-025-00205-7
165. Novel CAR T Therapy Earns FDA Breakthrough Status for Incurable Pediatric Brain Tumor, accessed May 24, 2025, https://www.targetedonc.com/view/novel-car-t-therapy-earns-fda-breakthrough-status-for-incurable-pediatric-brain-tumor
166. Cell Gene Therapies Will 2025 Represent A Continuation Of FDA's 2024 Developments, accessed May 24, 2025, https://www.cellandgene.com/doc/cell-gene-therapies-will-represent-a-continuation-of-fda-s-developments-0001
167. Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA | Nasdaq, accessed May 24, 2025, https://www.nasdaq.com/press-release/gilead-and-kite-announce-presentation-transformative-data-1l-metastatic-triple
168. Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11869864/
169. Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma | Blood Advances | American Society of Hematology, accessed May 24, 2025, https://ashpublications.org/bloodadvances/article/9/4/704/534321/Dual-targeting-CAR-T-cells-for-B-cell-acute
170. Editorial: The mechanism and novel strategies of overcoming resistance of hematological malignancies to CAR-T cell killing - Frontiers, accessed May 24, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1093339/full
171. Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia, accessed May 24, 2025, https://www.researchgate.net/publication/384264462_Overcoming_Antigen_Escape_and_T-Cell_Exhaustion_in_CAR-T_Therapy_for_Leukemia
172. (PDF) Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma - ResearchGate, accessed May 24, 2025, https://www.researchgate.net/publication/391368766_Advances_and_challenges_in_CAR-T_cell_therapy_for_head_and_neck_squamous_cell_carcinoma
173. Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy - MDPI, accessed May 24, 2025, https://www.mdpi.com/2072-6694/17/5/880
174. KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL). - ASCO, accessed May 24, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT362116
175. With More Experience, CAR T-cell Therapies Come Into Better Focus | Blood Cancers Today, accessed May 24, 2025, https://www.bloodcancerstoday.com/post/with-more-experience-car-t-cell-therapies-come-into-better-focus
176. Evolving strategies for addressing CAR T-cell toxicities - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11646216/
177. Investigators Focus on Reducing On-Target, Off-Tumor Toxicities With CAR T-Cell Therapy in Solid Tumors - OncLive, accessed May 24, 2025, https://www.onclive.com/view/investigators-focus-on-reducing-on-target-off-tumor-toxicities-with-car-t-cell-therapy-in-solid-tumors
178. INSPIRED Symposium Part 4B: Chimeric Antigen Receptor T Cell Correlative Studies—Established Findings and Future Priorities - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12047531/
179. Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference, accessed May 24, 2025, https://ir.lyell.com/news-releases/news-release-details/lyell-highlight-vision-its-next-generation-car-t-cell-therapy/
180. Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphoma - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11195421/
181. Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy - Translational Cancer Research, accessed May 24, 2025, https://tcr.amegroups.org/article/view/45736/html
182. Targeting Cancer: Microenvironment and Immunotherapy Innovations - MDPI, accessed May 24, 2025, https://www.mdpi.com/1422-0067/25/24/13569
183. Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas - Frontiers, accessed May 24, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1110028/full
184. Allogene's Dual-Acting CAR T Candidate ALLO-329 Gets FDA Green Light for Autoimmune Disease Trial - CRISPR Medicine News, accessed May 24, 2025, https://crisprmedicinenews.com/news/allogenes-dual-acting-car-t-candidate-allo-329-gets-fda-green-light-for-autoimmune-disease-trial/
185. Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma - GlobeNewswire, accessed May 24, 2025, https://www.globenewswire.com/news-release/2025/04/07/3056719/0/en/Allogene-Granted-Three-U-S-FDA-Fast-Track-Designations-FTD-for-ALLO-329-a-Next-Generation-Dual-Targeted-CD19-CD70-Allogeneic-CAR-T-for-the-Treatment-of-Lupus-Myositis-and-Scleroder.html
186. Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies - PubMed, accessed May 24, 2025, https://pubmed.ncbi.nlm.nih.gov/39946666/
187. Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies | Blood Advances | American Society of Hematology, accessed May 24, 2025, https://ashpublications.org/bloodadvances/article/9/7/1644/535452/Allogeneic-off-the-shelf-CAR-T-cell-therapy-for
188. Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies | Journal of Clinical Oncology - ASCO Publications, accessed May 24, 2025, https://ascopubs.org/doi/10.1200/JCO-24-01933
189. Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Ly - ASCO Publications, accessed May 24, 2025, https://ascopubs.org/doi/pdf/10.1200/JCO-24-01933
190. Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Ly, accessed May 24, 2025, https://allogene.com/wp-content/uploads/2025/04/locke-et-al-2025-allogeneic-chimeric-antigen-receptor-t-cell-products-cemacabtagene-ansegedleucel-allo-501-in-relapsed.pdf
191. ALLOGENEIC CD19-TARGETED CAR-T THERAPY FOR REFRACTORY MODERATE TO... by Biao Zheng - EHA Library, accessed May 24, 2025, https://library.ehaweb.org/eha/2025/eha2025-congress/4162568/biao.zheng.allogeneic.cd19-targeted.car-t.therapy.for.refractory.moderate.to.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31576%2Amarker%3D5845%2Afeatured%3D19595
192. Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors - Frontiers, accessed May 24, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1546717/full
193. Revving the CAR – Combination strategies to enhance CAR T cell effectiveness, accessed May 24, 2025, https://www.researchgate.net/publication/341155358_Revving_the_CAR_-_Combination_strategies_to_enhance_CAR_T_cell_effectiveness
194. Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12036236/
195. Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies - PMC, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11700040/
196. The current socioeconomic and regulatory landscape of immune effector cell therapies, accessed May 24, 2025, https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1462307/full
197. Full article: Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma, accessed May 24, 2025, https://www.tandfonline.com/doi/full/10.2217/fon-2022-0162
198. Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial - ResearchGate, accessed May 24, 2025, https://www.researchgate.net/publication/391401777_Axicabtagene_ciloleucel_compared_to_standard_of_care_in_Canadian_patients_with_relapsed_or_refractory_large_B-cell_lymphoma_a_cost-effectiveness_analysis_of_the_ZUMA-7_trial
199. Liso-cel Versus Mosunetuzumab in Follicular Lymphoma: Cost, Clinical Outcomes, Time Toxicity | Blood Cancers Today, accessed May 24, 2025, https://www.bloodcancerstoday.com/post/liso-cel-versus-mosunetuzumab-in-follicular-lymphoma-cost-clinical-outcomes-time-toxicity
200. Cost-effectiveness studies of brexu-cel for Relapsed/Refractory B-Cell acute lymphoblastic leukemia and Mantle Cell Lymphoma: a systematic review | Request PDF - ResearchGate, accessed May 24, 2025, https://www.researchgate.net/publication/386456991_Cost-effectiveness_studies_of_brexu-cel_for_RelapsedRefractory_B-Cell_acute_lymphoblastic_leukemia_and_Mantle_Cell_Lymphoma_a_systematic_review
201. High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions, accessed May 24, 2025, https://ascopubs.org/doi/10.1200/EDBK_397912
202. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma - PMC, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10011202/
203. Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed/refractory mantle cell lymphoma in the United States, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11871159/
204. Autolus Therapeutics to Present Data at 2025 Tandem Meetings on AUCATZYL® and Its Economic Impact Compared to CAR-T Therapies | Nasdaq, accessed May 24, 2025, https://www.nasdaq.com/articles/autolus-therapeutics-present-data-2025-tandem-meetings-aucatzylr-and-its-economic-impact
205. COMy 2025: CAR T-Cell Therapy Access Gaps in Myeloma - EMJ, accessed May 24, 2025, https://www.emjreviews.com/hematology/news/comy-2025-car-t-cell-therapy-access-gaps-in-myeloma/
206. Socioeconomic, racial-ethnic, household, and infrastructural disparities of hematologic cancer outcomes in the United States - ASH Publications, accessed May 24, 2025, https://ashpublications.org/bloodadvances/article/9/6/1463/535057/Socioeconomic-racial-ethnic-household-and
207. Socioeconomic, racial-ethnic, household, and infrastructural disparities of hematologic cancer outcomes in the United States - PubMed, accessed May 24, 2025, https://pubmed.ncbi.nlm.nih.gov/39808792/
208. From the Editors: Cell & Gene Therapy Approvals in 2024 - ISCT, accessed May 24, 2025, https://www.isctglobal.org/telegrafthub/blogs/ken-ip1/2025/01/16/cell-gene-therapy-approvals-in-2024
209. FDA Activity Recap: January 2025 Features CRL, Multiple Clinical Holds, and More, accessed May 24, 2025, https://www.cgtlive.com/view/fda-activity-recap-january-2025-features-crl-multiple-clinical-holds-more
210. A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies, accessed May 24, 2025, https://bookcafe.yuntsg.com/ueditor/jsp/upload/file/20250211/1739272897953013482.pdf
211. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors - ResearchGate, accessed May 24, 2025, https://www.researchgate.net/publication/387758287_Advances_in_CAR_T_cell_therapy_antigen_selection_modifications_and_current_trials_for_solid_tumors
212. Novel CAR T Earns FDA RMAT Designation for Incurable Pediatric Brain Tumor, accessed May 24, 2025, https://www.targetedonc.com/view/novel-car-t-earns-fda-rmat-designation-for-incurable-pediatric-brain-tumor
213. Cell-Based Therapies in GI Cancers: Current Landscape and Future Directions, accessed May 24, 2025, https://ascopubs.org/doi/10.1200/EDBK-25-471716
214. Mechanistic Evaluation of Anti‐CD19 CAR‐T Cell Therapy Repurposed in Systemic Lupus Erythematosus Using a Quantitative Systems Pharmacology Model - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11815715/
215. Hematology Experts Outline the Top Abstracts to Watch at the 2025 ASCO Annual Meeting, accessed May 24, 2025, https://www.onclive.com/view/hematology-experts-outline-the-top-abstracts-to-watch-at-the-2025-asco-annual-meeting
216. Annual Meeting - ASCO, accessed May 24, 2025, https://www.asco.org/annual-meeting
217. ASCO 2025 Preview: Practice-Changing Trials to Watch - Targeted Oncology, accessed May 24, 2025, https://www.targetedonc.com/view/asco-2025-preview-practice-changing-trials-to-watch
218. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4861363/
219. A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies - ResearchGate, accessed May 24, 2025, https://www.researchgate.net/publication/388224227_A_Review_of_CAR_T_Cells_and_Adoptive_T-Cell_Therapies_in_Lymphoid_and_Solid_Organ_Malignancies
220. Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®) - NCBI, accessed May 24, 2025, https://www.ncbi.nlm.nih.gov/books/n/pdqcis/CDR0000816140/
221. The academic point‐of‐care anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel (ARI‐0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B‐cell non‐Hodgkin lymphoma - ResearchGate, accessed May 24, 2025, https://www.researchgate.net/publication/375131322_The_academic_point-of-care_anti-CD19_chimeric_antigen_receptor_T-cell_product_varnimcabtagene_autoleucel_ARI-0001_cells_shows_efficacy_and_safety_in_the_treatment_of_relapsedrefractory_B-cell_non-Hodg
222. Q-TWiST analysis of pembrolizumab or placebo plus chemotherapy for patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer in KEYNOTE-859. | Journal of Clinical Oncology - ASCO Publications, accessed May 24, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.376
223. Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Primary analysis from the phase 2 PILOT study. - ASCO, accessed May 24, 2025, https://www.asco.org/posters/POSTER376390
224. Obe-Cel Produces Durable Remissions in Adult R/R B-ALL - OncLive, accessed May 24, 2025, https://www.onclive.com/view/obe-cel-produces-durable-remissions-in-adult-r-r-b-all
225. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium - ASCO Publications, accessed May 24, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.19.02104
226. Liso-Cel and Pirtobrutinib Add Options in R/R CLL, Underscoring the Importance of Proper Treatment Selection - OncLive, accessed May 24, 2025, https://www.onclive.com/view/liso-cel-and-pirtobrutinib-add-options-in-r-r-cll-underscoring-the-importance-of-proper-treatment-selection
227. Dana-Farber Research News 05.01.2025, accessed May 24, 2025, https://physicianresources.dana-farber.org/news/dana-farber-research-news-05-01-2025
228. Treatment of Older Patients With ALL - ASCO Publications, accessed May 24, 2025, https://ascopubs.org/doi/10.1200/EDBK-25-473298
229. Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL - OncLive, accessed May 24, 2025, https://www.onclive.com/view/obe-cel-elicits-high-mrd-negative-response-rates-in-r-r-b-all
230. Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline, accessed May 24, 2025, https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-to-Present-Data-at-ASCO-2025-Highlighting-Differentiated-Research-Platform-of-Oncology-Treatments-and-Innovative-Research-Pipeline/default.aspx
231. Prognostic value of circulating tumor DNA (ctDNA) detection by PhasED-Seq after axicabtagene ciloleucel (axi-cel) therapy in relapsed/refractory large B-cell lymphoma (LBCL). - ASCO, accessed May 24, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT502704
232. Assessing the Need for Extended Monitoring After Axi-Cel Infusion - Targeted Oncology, accessed May 24, 2025, https://www.targetedonc.com/view/assessing-the-need-for-extended-monitoring-after-axi-cel-infusion
233. Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] | Kaiser Permanente, accessed May 24, 2025, https://healthy.kaiserpermanente.org/colorado/health-wellness/health-encyclopedia/he.aggressive-b-cell-non-hodgkin-lymphoma-treatment-pdq-treatment---health-professional-information-nci.ncicdr0000816140
234. ABSTRACTS/PRESENTATIONS - AIDS Malignancy Consortium, accessed May 24, 2025, https://amcoperations.com/system/files/abstr-AMC%20Bibliography_21MAR2025.pdf
235. Chronic lymphocytic leukemia | HemOnc.org - A Hematology Oncology Wiki, accessed May 24, 2025, https://hemonc.org/wiki/Chronic_lymphocytic_leukemia
236. Hematological Oncology - ICML, accessed May 24, 2025, https://www.icml.ch/dam/jcr:3b88ae9e-a74f-4020-b771-95f06dcbcec9/17-ICML%20Abstract%20Book_red.pdf
237. Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum - ASCO Publications, accessed May 24, 2025, https://ascopubs.org/doi/10.1200/EDBK_349647
238. www.horizonscangeneesmiddelen.nl, accessed May 24, 2025, https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/export?publicatiedatum=2022-12-07
239. Overcoming chimeric antigen receptor-T (CAR-T) resistance with checkpoint inhibitors: Existing methods, challenges, clinical success, and future prospects: A comprehensive review | Request PDF - ResearchGate, accessed May 24, 2025, https://www.researchgate.net/publication/389233084_Overcoming_chimeric_antigen_receptor-T_CAR-T_resistance_with_checkpoint_inhibitors_Existing_methods_challenges_clinical_success_and_future_prospects_A_comprehensive_review
240. (PDF) Low Incidence of Invasive Fungal Disease Following CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Non-Hodgkin Lymphoma - ResearchGate, accessed May 24, 2025, https://www.researchgate.net/publication/361875352_Low_Incidence_of_Invasive_Fungal_Disease_Following_CD19_Chimeric_Antigen_Receptor_T-Cell_CAR-T_Therapy_for_Non-Hodgkin_Lymphoma
241. Emerging concepts in immuno-oncology: Insights from ... - ChemRxiv, accessed May 24, 2025, https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/677c0488fa469535b9fa119d/original/Immuno-Oncology_Co-occurrence_PP.pdf
242. Expert Recommendations for the Diagnosis, Treatment, and Management of Adult B-Cell Acute Lymphoblastic Leukemia in Latin America | JCO Global Oncology - ASCO Publications, accessed May 24, 2025, https://ascopubs.org/doi/10.1200/GO.22.00292
243. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy | Request PDF - ResearchGate, accessed May 24, 2025, https://www.researchgate.net/publication/359909744_BCMA-Targeted_Biologic_Therapies_The_Next_Standard_of_Care_in_Multiple_Myeloma_Therapy
244. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden - ASCO Publications, accessed May 24, 2025, https://ascopubs.org/doi/10.1200/EDBK_238691
245. Oncology | Page 55 - American Journal of Managed Care, accessed May 24, 2025, https://www.ajmc.com/compendium/oncology?p=9&page=55
246. Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review | JNCI Cancer Spectrum | Oxford Academic, accessed May 24, 2025, https://academic.oup.com/jncics/advance-article/doi/10.1093/jncics/pkaf036/8098057?searchresult=1
247. Case report: Bridging radiation therapy before chimeric antigen receptor T-cell therapy induces sustained remission in patients with relapsed/refractory double-expressor diffuse large B-cell lymphoma with localized compressive symptoms - Frontiers, accessed May 24, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1441404/full
248. AUTL - Autolus Therapeutics plc ADR Stock Price and Quote - FINVIZ.com, accessed May 24, 2025, https://finviz.com/quote.ashx?t=AUTL
249. ASCO 2025: The Presentations That May Shift the Cancer Care Paradigm - CancerNetwork, accessed May 24, 2025, https://www.cancernetwork.com/view/asco-2025-the-presentations-that-may-shift-the-cancer-care-paradigm
250. ASCO 2025 preview – late-breakers in focus | ApexOnco - Oncology Pipeline, accessed May 24, 2025, https://www.oncologypipeline.com/apexonco/asco-2025-preview-late-breakers-focus
251. Abstract Policies - Frequently Asked Questions - ASCO, accessed May 24, 2025, https://www.asco.org/annual-meeting/abstracts-presentations/abstract-policies-embargoes-exceptions/frequently-asked-questions
252. CAR-T CELLS SPECIFIC TOXICITIES AS MAJOR DETERMINANTS OF... by Angelica Barone - EHA Library, accessed May 24, 2025, https://library.ehaweb.org/eha/2025/eha2025-congress/4159359/angelica.barone.car-t.cells.specific.toxicities.as.major.determinants.of.html?f=
253. Late-Breaking Abstract Submission - The European Hematology Association (EHA), accessed May 24, 2025, https://ehaweb.org/congress/eha2025-congress/abstracts-and-awards/late-breaking-abstract-submission/
254. LATE-BREAKING ABSTRACT SUBMISSION TERMS AND CONDITIONS 2025 - The European Hematology Association (EHA), accessed May 24, 2025, https://ehaweb.org/assets/Uploads/Congresses/EHA2025/Abstracts/EHA2025-Late-Breaking-Abstract-Submission-TC-March-2025.pdf
255. Abstract & Clinical Case Submission - The European Hematology Association (EHA), accessed May 24, 2025, https://ehaweb.org/meetings/previous-meetings/7th-european-car-t-cell-meeting/abstract-submission-and-awards/
256. AACR Annual Meeting 2025: News and Highlights, accessed May 24, 2025, https://www.aacr.org/meeting/aacr-annual-meeting-2025/aacr-annual-meeting-2025-news-and-highlights/
257. Unleashing the Power of CAR T Cells: Insights from Day 3 of AACR IO, accessed May 24, 2025, https://www.aacr.org/blog/2025/02/27/unleashing-the-power-of-car-t-cells-insights-from-day-3-of-aacr-io/
258. Novel CAR T-Cell Therapy for Relapsed Refractory DLBCL Receives FDA Fast Track Designation | Docwire News, accessed May 24, 2025, https://www.docwirenews.com/post/novel-car-t-cell-therapy-for-relapsed-refractory-dlbcl-receives-fda-fast-track-designation
259. FDA Issues Fast Track Designation for New CAR T-Cell Therapy for Relapsed Refractory DLBCL | Blood Cancers Today, accessed May 24, 2025, https://www.bloodcancerstoday.com/post/fda-issues-fast-track-designation-for-new-car-t-cell-therapy-for-relapsed-refractory-dlbcl
260. Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic - Frontiers, accessed May 24, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1335424/full
261. What Does Tisagenlecleucel Do? - Patsnap Synapse, accessed May 24, 2025, https://synapse.patsnap.com/blog/what-does-tisagenlecleucel-do
262. CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10647582/
263. CD19 CAR-T cell therapy for Relapsed or Refractory Diffuse Large B Cell Lymphoma; Why does it Fail? - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10964476/
264. CTL019 Out of Specification MAP for ALL or DLBCL Patients - Clinical Trials at UCSD, accessed May 24, 2025, https://clinicaltrials.ucsd.edu/trial/NCT03601442
265. LV20.19 CAR T-Cell Therapy Yields 100% ORR and Manageable Toxicity in R/R MCL, accessed May 24, 2025, https://www.onclive.com/view/lv20-19-car-t-cell-therapy-yields-100-orr-and-manageable-toxicity-in-r-r-mcl
266. CAR T-Cell therapy for the management of mantle cell lymphoma - PMC - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10064560/
267. Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR). - ASCO, accessed May 24, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT452700
268. 7th European CAR T-cell Meeting - The European Hematology Association (EHA), accessed May 24, 2025, https://ehaweb.org/meetings/previous-meetings/7th-european-car-t-cell-meeting/
269. iwCAR-T 2025 Highlights – Unleashing the Next Frontier in Immunotherapy - Oncodaily, accessed May 24, 2025, https://oncodaily.com/insight/iwcar-t-273030
270. Predicting CAR T-cell toxicity: insurance for CAR crashes | Blood Advances | American Society of Hematology, accessed May 24, 2025, https://ashpublications.org/bloodadvances/article/9/2/335/535072/Predicting-CAR-T-cell-toxicity-insurance-for-CAR
271. ASH 2024: Poor Outcomes Observed Following Disease Progression After CD19-Directed CAR T-Cell Therapy | Lymphoma Research Foundation, accessed May 24, 2025, https://lymphoma.org/news/ash-2024-poor-outcomes-observed-following-disease-progression-after-cd19-directed-car-t-cell-therapy/
272. Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure. - NIH RePORTER, accessed May 24, 2025, https://reporter.nih.gov/project-details/11041192
273. ASH 2024: Focus on CAR-T | Blood Cancers Today, accessed May 24, 2025, https://www.bloodcancerstoday.com/conference/2024-ash-annual-meeting-car-t
274. Flash Forward: Blood Cancer Highlights and Insights From ASH 2024 | ASH News Daily | American Society of Hematology, accessed May 24, 2025, https://ashpublications.org/ashnewsdaily/blogs/8404/Flash-Forward-Blood-Cancer-Highlights-and-Insights
275. FDA Activity Recap: April 2025 Features Major Approval in RDEB, Multiple Breakthrough Therapy Designations, and More - CGTLive®, accessed May 24, 2025, https://www.cgtlive.com/view/fda-activity-recap-april-2025-features-major-approval-rdeb-multiple-breakthrough-therapy-designations
276. Most FDA and EMA Oncology Drug Approvals in Q1 2025 Were New Indications for Biologics and Biosimilars - Aptitude Health, accessed May 24, 2025, https://www.aptitudehealth.com/oncology-news/most-fda-and-ema-oncology-drug-approvals-in-q1-2025-were-new-indications-for-biologics-and-biosimilars/
277. Strategies to Overcome CAR T Roadblocks in the Real-World Practice Setting, accessed May 24, 2025, https://www.targetedonc.com/view/strategies-to-overcome-car-t-roadblocks-in-the-real-world-practice-setting
278. The Majority of New FDA and EMA Oncology Drug Approvals in Q4 2024 Were for Biologics and Biosimilars - Aptitude Health, accessed May 24, 2025, https://www.aptitudehealth.com/oncology-news/the-majority-of-new-fda-and-ema-oncology-drug-approvals-in-q4-2024-were-for-biologics-and-biosimilars/
279. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma - PubMed, accessed May 24, 2025, https://pubmed.ncbi.nlm.nih.gov/31959992/
280. (PDF) Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma, accessed May 24, 2025, https://www.researchgate.net/publication/381576378_Combination_Targeted_Therapy_in_Relapsed_Diffuse_Large_B-Cell_Lymphoma
281. CAR-T Cell Therapy and Beyond - Novartis, accessed May 24, 2025, https://www.novartis.com/research-and-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond
282. Chimeric Antigen Receptor (CAR) T-Cell Therapy markets - BioSpace, accessed May 24, 2025, https://www.biospace.com/press-releases/the-chimeric-antigen-receptor-car-t-cell-therapy-markets-to-reach-us-12-482-2-million-by-2035-exhibiting-impelled-by-technological-advancements-in-car-t-therapy
283. Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress, accessed May 24, 2025, https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-presents-clinical-data-updates-2025
284. Modeling Risk for Hypogammaglobulinemia, Infections, and Mortality with Chimeric Antigen Receptor (CAR) T-cell Therapy - NIH RePORTER, accessed May 24, 2025, https://reporter.nih.gov/project-details/10846794
285. Impact of COVID-19 infection on CAR-T therapy outcomes. - ASCO, accessed May 24, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT506176
286. Real-World Outcomes of Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Third-Line Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Single-Center Study - MDPI, accessed May 24, 2025, https://www.mdpi.com/2673-6357/6/1/3
287. Newest Articles | JCO Oncology Practice - ASCO Publications, accessed May 24, 2025, https://ascopubs.org/toc/jop/0/0
288. (PDF) Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia - ResearchGate, accessed May 24, 2025, https://www.researchgate.net/publication/385825846_Clinical_Insights_on_Brexucabtagene_Autoleucel_for_the_Treatment_of_Patients_with_Relapsed_or_Refractory_B-Cell_Acute_Lymphoblastic_Leukemia
289. One Step Ahead: Preventing Tumor Adaptation to Immune Therapy - ASCO Publications, accessed May 24, 2025, https://ascopubs.org/doi/10.1200/EDBK-25-481556
290. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium | Journal of Clinical Oncology - ASCO Publications, accessed May 24, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.22.01797
291. Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11909426/
292. Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma? - MDPI, accessed May 24, 2025, https://www.mdpi.com/2072-6694/17/10/1602
293. Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial - ResearchGate, accessed May 24, 2025, https://www.researchgate.net/publication/384357517_Patient-reported_outcomes_in_the_subpopulation_of_patients_with_mismatch_repair-deficientmicrosatellite_instability-high_primary_advanced_or_recurrent_endometrial_cancer_treated_with_dostarlimab_plus_
294. Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review - PMC, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12092082/
295. Prevalence of symptomatic toxicities for novel therapies in adult oncology trials - Oxford Academic, accessed May 24, 2025, https://academic.oup.com/jncics/advance-article-pdf/doi/10.1093/jncics/pkaf036/62786187/pkaf036.pdf
296. Phase 2 Study Supports Second-Line Axi-Cel in R/R LBCL - Targeted Oncology, accessed May 24, 2025, https://www.targetedonc.com/view/phase-2-study-supports-second-line-axi-cel-in-r-r-lbcl
297. Liso-cel Yields Meaningful Efficacy in R/R Mantle Cell Lymphoma - CancerNetwork, accessed May 24, 2025, https://www.cancernetwork.com/view/liso-cel-yields-meaningful-efficacy-in-r-r-mantle-cell-lymphoma
298. Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors - PMC, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11743624/
299. A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy - PMC, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12009579/
300. Identification of Adjustment Variables in Indirect Comparisons: A Rapid Review of CAR-T Therapies for Diffuse Large B-Cell Lymphoma - PubMed Central, accessed May 24, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12025827/
301. Treatment patterns, health care resource utilization, and costs of chimeric antigen receptor T-cell vs standard therapy for relapsed/refractory mantle cell lymphoma in the United States, accessed May 24, 2025, https://www.jmcp.org/doi/10.18553/jmcp.2025.31.3.262
302. Federal Register/Vol. 90, No. 82/Wednesday, April 30, 2025/Proposed Rules - GovInfo, accessed May 24, 2025, https://www.govinfo.gov/content/pkg/FR-2025-04-30/pdf/2025-06271.pdf